| Year |
Citation |
Score |
| 2024 |
Meyer ML, Hirsch FR, Bunn PA, Ujhazy P, Fredrickson D, Berg CD, Carbone DP, Halmos B, Singh H, Borghaei H, Ferris A, Langer C, Dacic S, Mok TS, Peters S, et al. Calls to action on lung cancer management and research. The Oncologist. PMID 39002167 DOI: 10.1093/oncolo/oyae169 |
0.344 |
|
| 2024 |
Peters S, Gadgeel SM, Mok T, Nadal E, Kilickap S, Swalduz A, Cadranel J, Sugawara S, Chiu CH, Yu CJ, Moskovitz M, Tanaka T, Nersesian R, Shagan SM, Maclennan M, et al. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial. Nature Medicine. PMID 38898120 DOI: 10.1038/s41591-024-03008-4 |
0.383 |
|
| 2024 |
Repetto M, Chiara Garassino M, Loong HH, Lopez-Rios F, Mok T, Peters S, Planchard D, Popat S, Rudzinski ER, Drilon A, Zhou C. NTRK gene fusion testing and management in lung cancer. Cancer Treatment Reviews. 127: 102733. PMID 38733648 DOI: 10.1016/j.ctrv.2024.102733 |
0.36 |
|
| 2024 |
Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Trukhin D, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Kohlmann M, ... ... Mok TS, et al. A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study. Clinical Lung Cancer. PMID 38584069 DOI: 10.1016/j.cllc.2024.03.003 |
0.347 |
|
| 2024 |
Cheung AH, Wong KY, Chau SL, Xie F, Mui Z, Li GY, Li MSC, Tong J, Ng CS, Mok TS, Kang W, To KF. SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant. Pathology. PMID 38413251 DOI: 10.1016/j.pathol.2023.12.414 |
0.39 |
|
| 2024 |
Dziadziuszko R, Peled N, Mok T, Peters S, Aix SP, Alatorre-Alexander J, Vicuna BD, Maclennan M, Bhagawati-Prasad V, Shagan SM, Schleifman E, Ruf T, Mathisen MS, Gadgeel SM. High-dose alectinib for fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial. Contemporary Oncology (Poznan, Poland). 27: 217-223. PMID 38405208 DOI: 10.5114/wo.2023.135246 |
0.317 |
|
| 2024 |
Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR, Wu YL, Gainor J, Lee SH, Chiu CH, Kim SW, Yang CT, Wu CL, Wu L, Lin MC, et al. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2301017. PMID 38252907 DOI: 10.1200/JCO.23.01017 |
0.452 |
|
| 2023 |
Gridelli C, Peters S, Mok T, Garassino M, Paz-Ares L, Attili I, de Marinis F. Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT). Lung Cancer (Amsterdam, Netherlands). 187: 107441. PMID 38141488 DOI: 10.1016/j.lungcan.2023.107441 |
0.438 |
|
| 2023 |
Mok T, Jänne PA, Nishio M, Novello S, Reck M, Steuer C, Wu YL, Fougeray R, Fan PD, Meng J, Sternberg DW, Esker S, Yu HA. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced -mutated NSCLC after a third-generation EGFR TKI. Future Oncology (London, England). PMID 38095056 DOI: 10.2217/fon-2023-0602 |
0.462 |
|
| 2023 |
Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Medic N, Mann H, ... ... Mok T, et al. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). Lung Cancer (Amsterdam, Netherlands). 186: 107422. PMID 37992595 DOI: 10.1016/j.lungcan.2023.107422 |
0.453 |
|
| 2023 |
Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With Mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 41: 2869-2876. PMID 37235976 DOI: 10.1200/JCO.22.02547 |
0.43 |
|
| 2023 |
Zhou Q, Soo RA, Chang GC, Chiu CH, Hayashi H, Kim SW, Teraoka S, Goto Y, Zhou J, Ho-Fun Lee V, Kim DW, Han B, Chung Man Ho J, Lin CC, Lu S, ... ... Mok T, et al. Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced -Positive NSCLC. Jto Clinical and Research Reports. 4: 100499. PMID 37223611 DOI: 10.1016/j.jtocrr.2023.100499 |
0.365 |
|
| 2023 |
Chmielecki J, Mok T, Wu YL, Han JY, Ahn MJ, Ramalingam SS, John T, Okamoto I, Yang JC, Shepherd FA, Bulusu KC, Laus G, Collins B, Barrett JC, Hartmaier RJ, et al. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature Communications. 14: 1071. PMID 36849516 DOI: 10.1038/s41467-023-35962-x |
0.452 |
|
| 2023 |
Cheng Y, Zhou Q, Han B, Fan Y, Shan L, Chang J, Sun S, Fang J, Chen Y, Sun J, Wu G, Mann H, Naicker K, Shire N, Mok T, et al. NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 178: 87-95. PMID 36806898 DOI: 10.1016/j.lungcan.2023.01.013 |
0.424 |
|
| 2022 |
Mazieres J, Iadeluca L, Shaw AT, Solomon BJ, Bauer TM, de Marinis F, Felip E, Goto Y, Kim DW, Mok T, Reisman A, Thurm H, Polli AM, Liu G. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 174: 146-156. PMID 36410210 DOI: 10.1016/j.lungcan.2022.11.004 |
0.424 |
|
| 2022 |
Mitsudomi T, Tan D, Yang JC, Ahn MJ, Batra U, Cho BC, Cornelio G, Lim T, Mok T, Prabhash K, Reungwetwattana T, Ren SX, Singh N, Toyooka S, Wu YL, et al. Expert consensus recommendations on biomarker testing in metastatic and non-metastatic non-small cell lung cancer in Asia. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 36379356 DOI: 10.1016/j.jtho.2022.10.021 |
0.434 |
|
| 2022 |
Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Shi X, ... ... Mok T, et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2200975. PMID 36327426 DOI: 10.1200/JCO.22.00975 |
0.353 |
|
| 2022 |
Li M, Mok K, Mok T. A Detouring Experience Not Recommended: Lessons Learned from PF00299804. Cancer Research. 82: 3662-3664. PMID 36245245 DOI: 10.1158/0008-5472.CAN-22-2638 |
0.437 |
|
| 2022 |
de Castro G, Rizvi NA, Schmid P, Syrigos K, Martin C, Yamamoto N, Cheng Y, Moiseyenko V, Summers Y, Vynnychenko I, Lee SY, Bryl M, Zer A, Erman M, Timcheva C, ... ... Mok T, et al. NEPTUNE: Phase III Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 36240972 DOI: 10.1016/j.jtho.2022.09.223 |
0.334 |
|
| 2022 |
Ou SI, Nishio M, Ahn MJ, Mok T, Barlesi F, Zhou C, Felip E, de Marinis F, Kim SW, Pérol M, Liu G, Migliorino MR, Kim DW, Novello S, Bearz A, et al. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 36096442 DOI: 10.1016/j.jtho.2022.08.018 |
0.392 |
|
| 2022 |
Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, ... ... Mok T, et al. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nature Medicine. PMID 35995953 DOI: 10.1038/s41591-022-01933-w |
0.448 |
|
| 2022 |
Chen K, Yang A, Carbone DP, Kanu N, Liu K, Wang R, Nie Y, Shen H, Bai J, Wu L, Li H, Shi Y, Mok T, Yu J, Yang F, et al. Spatiotemporal genomic analysis reveals distinct molecular features in recurrent stage I non-small cell lung cancers. Cell Reports. 40: 111047. PMID 35830809 DOI: 10.1016/j.celrep.2022.111047 |
0.321 |
|
| 2022 |
Johnson M, Garassino MC, Mok T, Mitsudomi T. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer (Amsterdam, Netherlands). 170: 41-51. PMID 35714425 DOI: 10.1016/j.lungcan.2022.05.011 |
0.39 |
|
| 2022 |
Solomon BJ, Bauer TM, Ignatius Ou SH, Liu G, Hayashi H, Bearz A, Penkov K, Wu YL, Arrieta O, Jassem J, Calella AM, Peltz G, Polli A, Thurm H, Mok T. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With -Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102278. PMID 35605188 DOI: 10.1200/JCO.21.02278 |
0.454 |
|
| 2022 |
Dziadziuszko R, Peters S, Mok T, Camidge DR, Gadgeel SM, Ou SI, Konopa K, Noé J, Nowicka M, Bordogna W, Morcos PN, Smoljanovic V, Shaw AT. Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35275991 DOI: 10.1158/1078-0432.CCR-21-2840 |
0.382 |
|
| 2022 |
West HJ, McCleland M, Cappuzzo F, Reck M, Mok TS, Jotte RM, Nishio M, Kim E, Morris S, Zou W, Shames D, Das Thakur M, Shankar G, Socinski MA. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in mutated non-small cell lung cancer with , or comutations: subgroup results from the phase III IMpower150 trial. Journal For Immunotherapy of Cancer. 10. PMID 35190375 DOI: 10.1136/jitc-2021-003027 |
0.465 |
|
| 2021 |
Passaro A, Jänne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nature Cancer. 2: 377-391. PMID 35122001 DOI: 10.1038/s43018-021-00195-8 |
0.44 |
|
| 2021 |
Chang J, Wu YL, Lu S, Wang J, Mok T, Zhang L, Feng J, Wu L, Tu HY, Zhang Y, Luft A, Zhou JY, Ma Z, Lu Y, Hu C, et al. Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 165: 71-81. PMID 35093625 DOI: 10.1016/j.lungcan.2021.12.009 |
0.407 |
|
| 2021 |
Horn L, Wang Z, Wu G, Poddubskaya E, Mok T, Reck M, Wakelee H, Chiappori AA, Lee DH, Breder V, Orlov S, Cicin I, Cheng Y, Liu Y, Fan Y, et al. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. Jama Oncology. PMID 34473194 DOI: 10.1001/jamaoncol.2021.3523 |
0.417 |
|
| 2021 |
Dziadziuszko R, Mok T, Peters S, Han JY, Alatorre-Alexander J, Leighl N, Sriuranpong V, Pérol M, de Castro Junior G, Nadal E, de Marinis F, Frontera OA, Tan DSW, Lee DH, Kim HR, et al. Blood First Assay Screening Trial (BFAST) in Treatment-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 34311110 DOI: 10.1016/j.jtho.2021.07.008 |
0.317 |
|
| 2021 |
Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, Bivona T, Diehn M, Dive C, Dziadziuszko R, Leighl N, Malapelle U, Mok T, Peled N, Raez LE, et al. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 34246791 DOI: 10.1016/j.jtho.2021.06.017 |
0.365 |
|
| 2021 |
Cheng Y, Mok TS, Zhou X, Lu S, Zhou Q, Zhou J, Du Y, Yu P, Liu X, Hu C, Lu Y, Zhang Y, Lee KH, Nakagawa K, Linke R, et al. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer (Amsterdam, Netherlands). 154: 176-185. PMID 33721611 DOI: 10.1016/j.lungcan.2021.02.025 |
0.448 |
|
| 2021 |
Garrido P, Pujol JL, Kim ES, Lee JM, Tsuboi M, Gómez-Rueda A, Benito A, Moreno N, Gorospe L, Dong T, Blin C, Rodrik-Outmezguine V, Passos VQ, Mok TS. Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design. Future Oncology (London, England). PMID 33648347 DOI: 10.2217/fon-2020-1098 |
0.358 |
|
| 2021 |
Kim ES, Barlesi F, Mok T, Ahn MJ, Shen J, Zhang P, Ou SI. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. Future Oncology (London, England). PMID 33569983 DOI: 10.2217/fon-2020-1119 |
0.474 |
|
| 2021 |
Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, Garassino MC, De Castro Carpeno J, Califano R, Nishio M, Orlandi F, Alatorre-Alexander J, Leal T, Cheng Y, Lee JS, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001055. PMID 33439693 DOI: 10.1200/JCO.20.01055 |
0.347 |
|
| 2020 |
Mok T, Peters S, Camidge DR, Noé J, Gadgeel S, Ignatius Ou SH, Kim DW, Konopa K, Pozzi E, Liu T, Loftin IR, Williams C, Shaw AT. Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 34756882 DOI: 10.1016/j.jtho.2020.10.007 |
0.43 |
|
| 2020 |
Passaro A, Mok T, Peters S, Popat S, Ahn MJ, De Marinis F. Recent Advances on the Role of EGFR TKIs in the Management of NSCLC with Uncommon, non-exon 20 insertion EGFR Mutations. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33333327 DOI: 10.1016/j.jtho.2020.12.002 |
0.4 |
|
| 2020 |
Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Chawla A, Rosell R, Corral J, Migliorino MR, Pluzanski A, Noonan K, Tang Y, Pastel M, Wilner KD, et al. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs. PMID 33331989 DOI: 10.1007/s40265-020-01441-6 |
0.519 |
|
| 2020 |
Lu S, Wang J, Cheng Y, Mok T, Chang J, Zhang L, Feng J, Tu HY, Wu L, Zhang Y, Luft A, Zhou JY, Ma Z, Lu Y, Hu C, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). Lung Cancer (Amsterdam, Netherlands). 152: 7-14. PMID 33321441 DOI: 10.1016/j.lungcan.2020.11.013 |
0.433 |
|
| 2020 |
Wu YL, Zhang L, Fan Y, Zhou J, Zhang L, Zhou Q, Li W, Hu C, Chen G, Zhang X, Zhou C, Dang T, Sadowski S, Kush DA, Zhou Y, ... ... Mok T, et al. Randomized Clinical Trial of Pembrolizumab Versus Chemotherapy for Previously Untreated Chinese Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: KEYNOTE-042 China Study. International Journal of Cancer. PMID 33231285 DOI: 10.1002/ijc.33399 |
0.354 |
|
| 2020 |
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ. First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. The New England Journal of Medicine. 383: 2018-2029. PMID 33207094 DOI: 10.1056/NEJMoa2027187 |
0.45 |
|
| 2020 |
Paty J, Sandin R, Reisman A, Wu YL, Migliorino MR, Zhou X, Cheng Y, Lee KH, Nakagawa K, Niho S, Corral J, Płużański A, Linke R, Meyers O, Mok TS. The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050. Future Oncology (London, England). PMID 33164569 DOI: 10.2217/fon-2020-0888 |
0.313 |
|
| 2020 |
Burns TF, Borghaei H, Ramalingam SS, Mok TS, Peters S. Targeting -Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on Mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000744. PMID 33104438 DOI: 10.1200/JCO.20.00744 |
0.331 |
|
| 2020 |
Chan SL, Yip TC, Wong VW, Tse YK, Yuen BW, Luk HW, Lui RN, Chan HL, Mok TS, Wong GL. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study. Cancer Medicine. PMID 32780516 DOI: 10.1002/Cam4.3378 |
0.316 |
|
| 2020 |
Chau SL, Tong JH, Chow C, Kwan JS, Lung RW, Chung LY, Tin EK, Wong SS, Cheung AH, Lau RW, Ng CS, Mok TS, Lo KW, To KF. Distinct Molecular Landscape of Epstein-Barr Virus Associated Pulmonary Lymphoepithelioma-Like Carcinoma Revealed by Genomic Sequencing. Cancers. 12. PMID 32726920 DOI: 10.3390/Cancers12082065 |
0.37 |
|
| 2020 |
Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, Huang M, Yi X, Liang M, Wang Y, Shen H, Tong R, Wang W, Li L, Song J, ... ... Mok T, et al. Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nature Medicine. PMID 32555427 DOI: 10.1038/S41591-020-0973-6 |
0.446 |
|
| 2020 |
Rolfo C, Cardona AF, Cristofanilli M, Paz-Ares L, Diaz Mochon JJ, Duran I, Raez LE, Russo A, Lorente JA, Malapelle U, Gil-Bazo I, Jantus-Lewintre E, Pauwels P, Mok T, Serrano MJ, et al. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Critical Reviews in Oncology/Hematology. 151: 102978. PMID 32428812 DOI: 10.1016/J.Critrevonc.2020.102978 |
0.302 |
|
| 2020 |
Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, Huang M, Yi X, Liang M, Wang Y, Shen H, Tong R, Wang W, Li L, Song J, ... ... Mok T, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nature Medicine. PMID 32341578 DOI: 10.1038/S41591-020-0840-5 |
0.419 |
|
| 2020 |
Paz-Ares L, Garon EB, Mok T, Ardizzoni A, Barlesi F, Cho BC, Castro Gd, Marchi PD, Felip E, Goto Y, Greystoke A, Lu S, Lim DW, Reck M, Solomon BJ, et al. Abstract CT286: CANOPY program clinical trials: Canakinumab (Cana) in patients (pts) with non-small cell lung cancer (NSCLC) Tumor Biology. DOI: 10.1158/1538-7445.Am2020-Ct286 |
0.471 |
|
| 2020 |
Horn L, Liu SV, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, Garassino MC, Carpeno JDC, Califano R, Nishio M, Orlandi F, Alexander JAA, Leal T, Cheng Y, Lee J, et al. Abstract CT220: IMpower133: Updated OS and exploratory analyses of first-line (1L) atezolizumab (atezo) + carboplatin (C) + etoposide (E) in extensive-stage SCLC (ES-SCLC) Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct220 |
0.408 |
|
| 2020 |
Socinski MA, Mok TS, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kong S, Liu X, et al. Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct216 |
0.5 |
|
| 2020 |
Lee JM, Garrido P, Kim ES, Arslan C, Pujol J, Song Y, Blin C, Rodrik-Outmezguine V, Mookerjee B, Passos V, Mok T. Abstract CT192: Randomized phase II study of canakinumab (CAN) or pembrolizumab (PEM) alone or in combination as neoadjuvant therapy in patients (Pts) with surgically resected (Stage IB-IIIA) non-small cell lung cancer (NSCLC): CANOPY-N Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct192 |
0.494 |
|
| 2020 |
Cho BC, Lopes G, Kowalski DM, Kasahara K, Wu Y, Castro G, Turna HZ, Cristescu R, Aurora-Garg D, Loboda A, Lunceford J, Kobie J, Ayers M, Pietanza MC, Piperdi B, ... Mok TS, et al. Abstract CT084: Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct084 |
0.4 |
|
| 2019 |
Ahn MJ, Chiu CH, Cheng Y, Han JY, Goldberg SB, Greystoke A, Crawford J, Zhao Y, Huang X, Johnson M, Vishwanathan K, Yates JWT, Brown AP, Mendoza-Naranjo A, Mok T. Osimertinib for patients with leptomeningeal metastases associated with epidermal growth factor receptor T790M positive advanced NSCLC: the AURA LM analysis. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31887431 DOI: 10.1016/J.Jtho.2019.12.113 |
0.426 |
|
| 2019 |
Nishio M, Felip E, Orlov S, Park K, Yu CJ, Tsai CM, Cobo M, McKeage M, Su WC, Mok T, Scagliotti GV, Spigel DR, Viraswami-Appanna K, Chen Z, Passos VQ, et al. Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naïve Patients With ALK-Rearranged Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31778798 DOI: 10.1016/J.Jtho.2019.11.006 |
0.529 |
|
| 2019 |
Papadimitrakopoulou VA, Han JY, Ahn MJ, Ramalingam SS, Delmonte A, Hsia TC, Laskin J, Kim SW, He Y, Tsai CM, Hida T, Maemondo M, Kato T, Jenkins S, Patel S, ... ... Mok T, et al. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer. PMID 31769875 DOI: 10.1002/Cncr.32503 |
0.527 |
|
| 2019 |
Woodford R, Loh Y, Lee J, Cooper W, Marschner I, Lewis CR, Millward M, Lord S, Gralla RJ, Yang JC, Mok T, Lee CK. Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. Future Oncology (London, England). 15: 2371-2383. PMID 31354046 DOI: 10.2217/Fon-2019-0105 |
0.364 |
|
| 2019 |
Corral J, Mok TS, Nakagawa K, Rosell R, Lee KH, Migliorino MR, Pluzanski A, Linke R, Devgan G, Tan W, Quinn S, Wang T, Wu YL. Effects of dose modifications on the safety and efficacy of dacomitinib for mutation-positive non-small-cell lung cancer. Future Oncology (London, England). PMID 31313942 DOI: 10.2217/Fon-2019-0299 |
0.453 |
|
| 2019 |
Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, ... ... Mok T, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer (Amsterdam, Netherlands). 133: 96-102. PMID 31200835 DOI: 10.1016/J.Lungcan.2019.05.011 |
0.555 |
|
| 2019 |
Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, et al. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 132: 126-131. PMID 31097085 DOI: 10.1016/J.Lungcan.2019.04.014 |
0.548 |
|
| 2019 |
Peters S, Reck M, Smit EF, Mok T, Hellmann MD. How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30912805 DOI: 10.1093/Annonc/Mdz109 |
0.424 |
|
| 2019 |
Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, et al. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30902613 DOI: 10.1016/J.Jtho.2019.03.007 |
0.537 |
|
| 2019 |
Zhou Q, Wu YL, Corral J, Nakagawa K, Garon EB, Sbar EI, Wang T, Sandin R, Noonan K, Gernhardt D, Mok TS. Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis. Future Oncology (London, England). PMID 30839234 DOI: 10.2217/Fon-2018-0944 |
0.44 |
|
| 2019 |
Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, et al. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. Journal of Cancer Research and Clinical Oncology. PMID 30783814 DOI: 10.1007/S00432-019-02862-X |
0.571 |
|
| 2019 |
Wu YL, Lu S, Cheng Y, Zhou C, Wang J, Mok T, Zhang L, Tu HY, Wu L, Feng J, Zhang Y, Luft AV, Zhou J, Ma Z, Lu Y, et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: CheckMate 078 Randomized Phase III Clinical Trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30659987 DOI: 10.1016/J.Jtho.2019.01.006 |
0.529 |
|
| 2019 |
Mansfield AS, Liu SV, Szczęsna A, Havel L, Kzrakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok TS, Lam S, Shames DS, Liu J, et al. Abstract CT199: IMpower133: Primary efficacy and safety + CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC) Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct199 |
0.396 |
|
| 2019 |
Socinski MA, Paul SM, Yun C, Hu S, Shen V, Velcheti V, Mok TS, Gandara DR, Chae YK, Schleifman E, Fabrizio DA, Shames DS, Phan S, Kim ES. Abstract CT194: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST—a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct194 |
0.415 |
|
| 2019 |
Park K, Yang JC, Girard N, Mok T, Gainor J, Nakagawa K, Wu Y, Xu W, Yang R, Ohe Y. Nivolumab + chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722) Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz343.039 |
0.5 |
|
| 2019 |
Tan A, Mok T, Kim D, Yang JC, Lee C, Soo R, Reungwetwattana T, Tan D, Loong H. P2.14-20 ATORG-003: Dacomitinib With or Without Dose Titration as First-Line Therapy for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.1805 |
0.522 |
|
| 2018 |
Dziadziuszko R, Mok TS, Camidge DR, Shaw AT, Noe J, Nowicka M, Liu T, Mitry E, Peters S. Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii494-viii495. PMID 32137278 DOI: 10.1093/Annonc/Mdy292.002 |
0.426 |
|
| 2018 |
Wu YL, Lee V, Liam CK, Lu S, Park K, Srimuninnimit V, Wang J, Zhou C, Appius A, Button P, Hooper G, Palma JF, Schulze K, Scudder S, Shames DS, ... ... Mok T, et al. Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. Lung Cancer (Amsterdam, Netherlands). 126: 1-8. PMID 30527172 DOI: 10.1016/J.Lungcan.2018.10.004 |
0.496 |
|
| 2018 |
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. The New England Journal of Medicine. PMID 30280641 DOI: 10.1056/Nejmoa1809064 |
0.427 |
|
| 2018 |
Loong HH, Kwan SS, Mok TS, Lau YM. Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer. Current Treatment Options in Oncology. 19: 58. PMID 30267319 DOI: 10.1007/S11864-018-0570-9 |
0.56 |
|
| 2018 |
Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, Lieber DS, Lipson D, Silterra J, Amler L, Riehl T, ... ... Mok T, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nature Medicine. PMID 30082870 DOI: 10.1038/S41591-018-0134-3 |
0.445 |
|
| 2018 |
Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, et al. Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET-Rearranged Lung Cancers. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30017832 DOI: 10.1016/J.Jtho.2018.07.004 |
0.424 |
|
| 2018 |
Wu YL, Lu S, Lu Y, Zhou J, Shi YK, Sriuranpong V, Ho JCM, Ong CK, Tsai CM, Chung CH, Wilner KD, Tang Y, Masters ET, Selaru P, Mok TS. Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29966800 DOI: 10.1016/J.Jtho.2018.06.012 |
0.558 |
|
| 2018 |
Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, et al. IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29885479 DOI: 10.1016/J.Jtho.2018.05.030 |
0.484 |
|
| 2018 |
Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, et al. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018787994. PMID 29864379 DOI: 10.1200/Jco.2018.78.7994 |
0.566 |
|
| 2018 |
Chan SL, Chan AWH, Mo F, Ma BBY, Wong KCW, Lam D, Mok FST, Chan ATC, Mok T, Chan KCA. Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer. The Oncologist. PMID 29802221 DOI: 10.1634/Theoncologist.2017-0637 |
0.33 |
|
| 2018 |
Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tang Y, Wilner KD, Blackhall F, Mok TS. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017774794. PMID 29768118 DOI: 10.1200/Jco.2017.77.4794 |
0.489 |
|
| 2018 |
Lee CK, Novello S, Rydén A, Mann H, Mok T. Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017772293. PMID 29733770 DOI: 10.1200/Jco.2017.77.2293 |
0.419 |
|
| 2018 |
Wu YL, Sequist LV, Tan EH, Geater SL, Orlov S, Zhang L, Lee KH, Tsai CM, Kato T, Barrios CH, Schuler M, Hirsh V, Yamamoto N, O'Byrne K, Boyer M, ... Mok T, et al. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clinical Lung Cancer. PMID 29653820 DOI: 10.1016/J.Cllc.2018.03.009 |
0.538 |
|
| 2018 |
Shukla ND, Salahudeen AA, Taylor GA, Ramalingam SS, Vokes EE, Goss GD, Decker RH, Kelly K, Scagliotti GV, Mok TS, Wakelee HA. Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. Clinical Lung Cancer. PMID 29653819 DOI: 10.1016/J.Cllc.2018.03.004 |
0.338 |
|
| 2018 |
Lee CK, Lord S, Marschner I, Wu YL, Sequist L, Rosell R, Fukuoka M, Mitsudomi T, Asher R, Davies L, Gebski V, Gralla R, Mok T, Chih-Hsin Yang J. The value of early depth of response in predicting long-term outcome in EGFR-mutant lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29580950 DOI: 10.1016/J.Jtho.2018.03.010 |
0.482 |
|
| 2018 |
Hsu WH, Yang JC, Mok TS, Loong HH. Overview of current systemic management of EGFR-mutant NSCLC. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: i3-i9. PMID 29462253 DOI: 10.1093/Annonc/Mdx702 |
0.545 |
|
| 2018 |
Karachaliou N, Chaib I, Cardona AF, Berenguer J, Bracht JWP, Yang J, Cai X, Wang Z, Hu C, Drozdowskyj A, Servat CC, Servat JC, Ito M, Attili I, Aldeguer E, ... ... Mok TS, et al. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. Ebiomedicine. PMID 29433983 DOI: 10.1016/J.Ebiom.2018.02.001 |
0.519 |
|
| 2018 |
Wu YL, Mok TS. Dacomitinib in NSCLC: a positive trial with little clinical impact - Authors' reply. The Lancet. Oncology. 19: e5. PMID 29304363 DOI: 10.1016/S1470-2045(17)30924-5 |
0.351 |
|
| 2018 |
Li L, Xu J, Qiu G, Ying J, Du Z, Xiang T, Wong KY, Srivastava G, Zhu XF, Mok TS, Chan AT, Chan FK, Ambinder RF, Tao Q. Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas. Theranostics. 8: 61-77. PMID 29290793 DOI: 10.7150/Thno.20893 |
0.316 |
|
| 2018 |
Lopes G, Wu Y, Kudaba I, Kowalski D, Cho BC, Castro G, Srimuninnimit V, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush DA, Mok T. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.18_Suppl.Lba4 |
0.433 |
|
| 2018 |
Horn L, Wu Y, Reck M, Wakelee HA, Liang C, Tan F, Harrow K, Oertel V, Dukart G, Mok T. eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps9115 |
0.491 |
|
| 2018 |
Karachaliou N, Chaib I, Cardona Zorrilla AF, Berenguer J, Bracht J, Yang J, Cai X, Wang Z, Drozdowskyj A, Attili I, Rodríguez JK, Rojas Puentes LL, Viteri Ramirez S, Ou SI, Mok T, et al. AXL and CDCP1: A roadmap of innate resistance in EGFR mutant NSCLC. Journal of Clinical Oncology. 36: e24003-e24003. DOI: 10.1200/Jco.2018.36.15_Suppl.E24003 |
0.377 |
|
| 2018 |
Hsu J, Jaminion F, Shaw A, Zhou C, Mok T, Tamura T, Tanaka T, Mitry E, Guerini E, Nüesch E, Balas B, Zeaiter AH, Morcos PN, Frey N. Population pharmacokinetics (PopPK) and exposure-response (ER) analyses to confirm the global alectinib (ALC) 600mg BID dose in the Chinese treatment-naïve population. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E21133 |
0.351 |
|
| 2018 |
Camidge DR, Peters S, Mok T, Gadgeel SM, Cheema PK, Pavlakis N, Marinis FD, Stroyakovskiy DL, Cho BC, Zhang L, Moro-Sibilot D, Zeaiter AH, Mitry E, Balas B, Müller B, et al. Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. Journal of Clinical Oncology. 36: 9043-9043. DOI: 10.1200/Jco.2018.36.15_Suppl.9043 |
0.391 |
|
| 2018 |
Shepherd FA, Papadimitrakopoulou V, Mok T, Wu Y, Han J, Ahn M, Ramalingam SS, John T, Sebastian M, Theelen W, Laus G, Collins B, Markovets A, Thress KS, Oxnard GR. Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial. Journal of Clinical Oncology. 36: 9027-9027. DOI: 10.1200/Jco.2018.36.15_Suppl.9027 |
0.478 |
|
| 2018 |
Mok T, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee MY, Linke RG, Rosell R, Jaime JC, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, et al. Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis. Journal of Clinical Oncology. 36: 9004-9004. DOI: 10.1200/Jco.2018.36.15_Suppl.9004 |
0.417 |
|
| 2018 |
Lieber DS, White E, Silterra J, Zhong S, Brennan T, Coyne M, Kennedy M, Gandara DR, Kowanetz M, Paul SM, Schleifman E, Li Y, Rittmeyer A, Fehrenbacher L, Amler L, ... ... Mok T, et al. Abstract A41: Analytic validation and clinical feasibility of a next-generation sequencing assay to assess tumor mutational burden from blood (bTMB) as a biomarker for anti-PD-L1 response in NSCLC Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A41 |
0.421 |
|
| 2018 |
Wu Y, Lu S, Cheng Y, Zhou C, Wang J, Mok T, Zhang L, Tu H, Wu L, Feng J, Zhang Y, Luft AV, Zhou J, Ma Z, Lu Y, et al. Abstract CT114: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct114 |
0.532 |
|
| 2018 |
Rittmeyer A, Gandara D, Kowanetz M, Mok T, Fehrenbacher L, Fabrizio D, Otto G, Malboeuf C, Lieber D, Paul S, Amler L, Riehl T, Schleifman E, Cummings C, Hegde P, et al. Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK) Pneumologie. 72: S49-S50. DOI: 10.1055/S-0037-1619250 |
0.389 |
|
| 2017 |
Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. Jama Oncology. PMID 29270615 DOI: 10.1001/Jamaoncol.2017.4427 |
0.503 |
|
| 2017 |
Mamdani H, Ahmed S, Armstrong S, Mok T, Jalal SI. Blood-based tumor biomarkers in lung cancer for detection and treatment. Translational Lung Cancer Research. 6: 648-660. PMID 29218268 DOI: 10.21037/Tlcr.2017.09.03 |
0.386 |
|
| 2017 |
Blackhall F, Ross Camidge D, Shaw AT, Soria JC, Solomon BJ, Mok T, Hirsh V, Jänne PA, Shi Y, Yang PC, Pas T, Hida T, Carpeño JC, Lanzalone S, Polli A, et al. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. Esmo Open. 2: e000219. PMID 29209525 DOI: 10.1136/esmoopen-2017-000219 |
0.441 |
|
| 2017 |
Wu YL, Hirsh V, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O'Byrne K, Geater SL, Zhou C, Massey D, Märten A, et al. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). The Patient. PMID 29178024 DOI: 10.1007/S40271-017-0287-Z |
0.557 |
|
| 2017 |
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, ... ... Mok TS, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. The Lancet. Oncology. PMID 28958502 DOI: 10.1016/S1470-2045(17)30608-3 |
0.559 |
|
| 2017 |
Li C, Huang C, Mok TS, Zhuang W, Xu H, Miao Q, Fan X, Zhu W, Huang Y, Lin X, Jiang K, Hu D, Chen X, Huang P, Lin G. Comparison of 22C3-PD-L1 expression between surgically resected specimens and paired tissue microarrays in non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28751245 DOI: 10.1016/J.Jtho.2017.07.015 |
0.336 |
|
| 2017 |
Yang JC, Mok T, Han B, Orlando M, Puri T, Park K. A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clinical Lung Cancer. PMID 28743421 DOI: 10.1016/J.Cllc.2017.06.013 |
0.536 |
|
| 2017 |
Yang S, Liu Y, Li MY, Ng CSH, Yang SL, Wang S, Zou C, Dong Y, Du J, Long X, Liu LZ, Wan IYP, Mok T, Underwood MJ, Chen GG. FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer. Molecular Cancer. 16: 124. PMID 28716029 DOI: 10.1186/S12943-017-0700-1 |
0.442 |
|
| 2017 |
Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, Hashigaki S, Ohki E, Usari T, Paolini J, Polli A, Wilner KD, Mok T. Crizotinib Versus Chemotherapy in Asian Patients with Advanced ALK-positive Non-small Cell Lung Cancer. Cancer Research and Treatment : Official Journal of Korean Cancer Association. PMID 28701030 DOI: 10.4143/Crt.2017.280 |
0.569 |
|
| 2017 |
Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. The Lancet. Oncology. PMID 28602779 DOI: 10.1016/S1470-2045(17)30339-X |
0.562 |
|
| 2017 |
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, ... ... Mok T, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine. PMID 28586279 DOI: 10.1056/Nejmoa1704795 |
0.475 |
|
| 2017 |
Mok TS, Wu YL, Papadimitrakopoulou VA. Osimertinib in EGFR T790M-Positive Lung Cancer. The New England Journal of Medicine. 376: 1993-4. PMID 28514610 DOI: 10.1056/NEJMc1703339#SA3 |
0.392 |
|
| 2017 |
Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, ... Mok T, et al. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. Journal of the National Cancer Institute. 109. PMID 28376144 DOI: 10.1093/Jnci/Djw279 |
0.572 |
|
| 2017 |
Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B, Chewaskulyong B, Sunpaweravong P, Ohe Y, Ichinose Y, Yang JJ, Mok TS, Young H, Haddad V, Rukazenkov Y, et al. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer (Amsterdam, Netherlands). 104: 119-125. PMID 28212993 DOI: 10.1016/j.lungcan.2016.11.022 |
0.484 |
|
| 2017 |
Zhao ZR, Situ DR, Lau RW, Mok TS, Chen GG, Underwood MJ, Ng CS. Comparison of segmentectomy and lobectomy in stage IA adenocarcinomas >1 and ≤2 cm: a brief report. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28111235 DOI: 10.1016/j.jtho.2017.01.012 |
0.307 |
|
| 2017 |
Wu YL, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Schuler M, Mok T, Yamamoto N, O'Byrne K, Hirsh V, Gibson N, Massey D, et al. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. British Journal of Cancer. 116: 175-185. PMID 28006816 DOI: 10.1038/Bjc.2016.420 |
0.519 |
|
| 2017 |
Lam KY, Lee K, Chong C, Chan AW, Mok T, Chan SL. A study on thromboembolism of patients with pancreatic cancer. Journal of Clinical Oncology. 35: 262-262. DOI: 10.1200/Jco.2017.35.4_Suppl.262 |
0.368 |
|
| 2017 |
Shaw AT, Peters S, Mok T, Gadgeel SM, Ahn JS, Ou SI, Perol M, Dziadziuszko R, Kim D, Rosell R, Zeaiter AH, Liu T, Golding S, Balas B, Noé J, et al. Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.18_Suppl.Lba9008 |
0.508 |
|
| 2017 |
Mok T, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Rosell R, Jaime JC, Migliorino MR, Pluzanski A, Linke RG, Sbar E, Wang T, Wu Y. Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial. Journal of Clinical Oncology. 35: 0. DOI: 10.1200/Jco.2017.35.18_Suppl.Lba9007 |
0.553 |
|
| 2017 |
Horn L, Mansfield AS, Reck M, Mok T, Spira AI, Tang X, Lam S, Kabbinavar FF, Lopez-Chavez A, Sandler A, Liu SV. Phase I/III trial of atezolizumab with carboplatin and etoposide in ES-SCLC in first-line setting (IMpower133). Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps8584 |
0.49 |
|
| 2017 |
Horn L, Wu Y, Reck M, Liang C, Tan F, Harrow K, Oertel V, Dukart G, Mok T. eXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps8578 |
0.451 |
|
| 2017 |
Lin G, Li C, Huang C, Fang RX, Xu PH, Lin Dx, Wu B, Chen X, Xu C, Mok T. Clinical significance of 22C3-PD-L1 IHC expression in surgically resected non-small cell lung cancer. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E20507 |
0.4 |
|
| 2017 |
Drilon AE, Filleron T, Bergagnini I, Milia J, Hatzoglou V, Velcheti V, Besse B, Mok T, Awad MM, Wolf J, Carbone DP, Camidge DR, Riely GJ, Peled N, Mazieres J, et al. Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers. Journal of Clinical Oncology. 35: 9069-9069. DOI: 10.1200/Jco.2017.35.15_Suppl.9069 |
0.444 |
|
| 2017 |
Mok T, Ahn M, Han J, Kang JH, Katakami N, Kim H, Hodge R, Ghiorghiu DC, Cantarini M, Wu Y, Papadimitrakopoulou V, Garassino MC. CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3). Journal of Clinical Oncology. 35: 9005-9005. DOI: 10.1200/Jco.2017.35.15_Suppl.9005 |
0.449 |
|
| 2017 |
Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon AE, Noonan S, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda YK, Clark JW, ... ... Mok T, et al. Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 35: 8511-8511. DOI: 10.1200/Jco.2017.35.15_Suppl.8511 |
0.502 |
|
| 2017 |
Hirsh V, Park K, Tan E, Zhang L, O’Byrne K, Boyer M, Yang J, Mok T, Lee K, Lu S, Shi Y, Kim S, Laskin J, Kim D, Laurie S, et al. Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7) European Journal of Cancer. 72: S184. DOI: 10.1016/S0959-8049(17)30670-6 |
0.535 |
|
| 2017 |
Schuler M, Paz-Ares L, Sequist LV, Tan EH, Mok T, Hirsh V, O’Byrne K, Zhang L, Yamamoto N, Boyer M, Shah R, Bennouna J, Dickgreber NJ, Grève JD, Love J, et al. First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials European Journal of Cancer. 72. DOI: 10.1016/S0959-8049(17)30648-2 |
0.503 |
|
| 2017 |
Gautschi O, Milia-Baron J, Filleron T, Wolf J, Carbone D, Owen D, Camidge DR, Narayanan V, Doebele R, Besse B, Remon J, Jänne P, Awad M, Peled N, Byoung C, ... ... Mok T, et al. MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.508 |
0.423 |
|
| 2017 |
Wu YL, Jenkins S, Ramalingam S, Han J, Delmonte A, Hsia T, Laskin J, Kim S, He Y, Patel S, Hodge R, Marotti M, Papadimitrakopoulou V, Mok T. MA08.03 Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma ctDNA Analysis Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.436 |
0.396 |
|
| 2017 |
Park K, Tan EH, Zhang L, Hirsh V, O'Byrne K, Boyer M, Chih-Hsin Yang J, Mok T, Lee KH, Lu S, Shi Y, Kim S, Laskin J, Kim D, Laurie S, et al. OA23.05 First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7 Journal of Thoracic Oncology. 12: S335-S336. DOI: 10.1016/J.Jtho.2016.11.363 |
0.503 |
|
| 2017 |
Park K, Tan EH, Zhang L, Hirsh V, O'Byrne K, Boyer M, Yang JC, Mok T, Peil B, Märten A, Paz-Ares L. P3.02b-044 Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged ≥75 Years: Subgroup Analysis of LUX-Lung 7: Topic: EGFR Clinical Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1711 |
0.513 |
|
| 2017 |
Mok T, Schmid P, Castro GD, Syrigos K, Martin C, Yamamoto N, Arén O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva C, Trani L. P2.06-022 First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study: Topic: Phase III Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1515 |
0.408 |
|
| 2017 |
Papadimitrakopoulou V, Wu YL, Ahn M, Ramalingam S, Garassino M, Kim HR, Shepherd F, Akamatsu H, Theelen W, Lee CK, Sebastian M, Templeton A, Marotti M, Ghiorghiu S, Mok T. PL03.03: Randomized Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3) Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.006 |
0.484 |
|
| 2016 |
Horn L, Reck M, Mok T, Johnson ML, Tang X, Lam S, Waterkamp D, Lopez-Chavez A, Sandler A, Giacconne G, Liu SV. PS01.57: IMpower133: a Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC: Topic: Medical Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S305-S306. PMID 27969524 DOI: 10.1016/J.Jtho.2016.09.092 |
0.314 |
|
| 2016 |
Jotte RM, Socinski MA, Reck M, Papadimitrakopoulou V, West HJ, Mok T, Sandler A, Mocci S, Coleman S, Asakawa T, Cappuzzo F. PS01.53: First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: Medical Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S302-S303. PMID 27969520 DOI: 10.1016/J.Jtho.2016.09.088 |
0.416 |
|
| 2016 |
Shaw AT, Spigel DR, Tan DS, Kim DW, Mehra R, Orlov S, Park K, Yu CJ, Mok T, Nishio M, Scagliotti G, Sutradhar S, Cesic D, Felip E. MINI01.01: Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3: Topic: Medical Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S256. PMID 27969450 DOI: 10.1016/J.Jtho.2016.09.016 |
0.369 |
|
| 2016 |
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. The New England Journal of Medicine. PMID 27959700 DOI: 10.1056/Nejmoa1612674 |
0.558 |
|
| 2016 |
Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Mocci S, Phan S, Shames DS, Smith D, Yu W, Paton VE, Mok T. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016692160. PMID 27937096 DOI: 10.1200/Jco.2016.69.2160 |
0.546 |
|
| 2016 |
Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, Yang JC. Brief report: Checkpoint inhibitors in metastatic EGFR mutated non-small-cell lung cancer - a meta-analysis. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 27765535 DOI: 10.1016/J.Jtho.2016.10.007 |
0.552 |
|
| 2016 |
De Lima Lopes G, Wu YL, Sadowski S, Zhang J, Rangwala R, Kush D, Mok T. P2.43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894): Track: Immunotherapy. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S244-S245. PMID 27676577 DOI: 10.1016/J.Jtho.2016.08.114 |
0.353 |
|
| 2016 |
Barrios CH, Wu YL, Chih-Hsin Yang J, Sequist LV, Geater SL, Mok T, Hu CP, Yamamoto N, O'Byrne K, Lu S, Hirsh V, Sebastian M, Okamoto I, Shah R, Märten A, et al. P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6: Track: Advanced NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S210-S211. PMID 27676531 DOI: 10.1016/J.Jtho.2016.08.067 |
0.381 |
|
| 2016 |
Aix SP, Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Chih-Hsin Yang J, Märten A, Paz-Ares L. P1.34: First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial: Track: Advanced NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S203-S204. PMID 27676520 DOI: 10.1016/J.Jtho.2016.08.056 |
0.506 |
|
| 2016 |
Fein L, Wu YL, Sequist LV, Geater SL, Orlov S, Lee KH, Tsai CM, Kato T, Kiura K, Barrios CH, Schuler M, Hirsh V, Yamamoto N, O'Byrne K, Mok T, et al. P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6: Track: Advanced NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S202-S203. PMID 27676519 DOI: 10.1016/J.Jtho.2016.08.055 |
0.528 |
|
| 2016 |
Salahudeen AA, Patel MI, Baas P, Curran WJ, Bradley JD, Gandara DR, Goss GD, Mok TS, Ramalingam SS, Vokes EE, Malik SM, Wakelee HA. Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe. Clinical Lung Cancer. PMID 27473736 DOI: 10.1016/j.cllc.2016.06.007 |
0.381 |
|
| 2016 |
Crinò L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, Mok T, Spigel D, Felip E, Nishio M, Scagliotti G, Branle F, Emeremni C, Quadrigli M, Zhang J, et al. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27432917 DOI: 10.1200/Jco.2015.65.5936 |
0.54 |
|
| 2016 |
Mok T, Ladrera G, Srimuninnimit V, Sriuranpong V, Yu CJ, Thongprasert S, Sandoval-Tan J, Lee JS, Fuerte F, Shames DS, Klughammer B, Truman M, Perez-Moreno P, Wu YL. Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 98: 1-8. PMID 27393499 DOI: 10.1016/J.Lungcan.2016.04.023 |
0.576 |
|
| 2016 |
Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, ... ... Mok TS, et al. The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation positive non-small cell lung cancer: status in 2016. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 27229180 DOI: 10.1016/J.Jtho.2016.05.008 |
0.465 |
|
| 2016 |
Mok T, Schmid P, Arén O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva K, Martin C, McIntosh S. 192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S140-1. PMID 27198329 DOI: 10.1016/S1556-0864(16)30301-X |
0.439 |
|
| 2016 |
Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. The Lancet. Oncology. PMID 27083334 DOI: 10.1016/S1470-2045(16)30033-X |
0.564 |
|
| 2016 |
Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27022118 DOI: 10.1200/JCO.2015.63.5888 |
0.454 |
|
| 2016 |
Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, ... ... Mok TS, et al. Scientific Advances in Lung Cancer 2015. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 27013409 DOI: 10.1016/J.Jtho.2016.03.012 |
0.483 |
|
| 2016 |
Tong JH, Yeung SF, Chan AW, Chung LY, Chau SL, Lung RW, Tong CY, Chow C, Tin EK, Yu YH, Li H, Pan Y, Chak WP, Ng CS, Mok TS, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of Non-small Cell Lung Carcinoma with poor prognosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26847053 DOI: 10.1158/1078-0432.CCR-15-2061 |
0.405 |
|
| 2016 |
Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26823294 DOI: 10.1016/J.Jtho.2015.11.014 |
0.577 |
|
| 2016 |
Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26811519 DOI: 10.1200/Jco.2015.64.8824 |
0.452 |
|
| 2016 |
Klughammer B, Brugger W, Cappuzzo F, Ciuleanu T, Mok T, Reck M, Tan EH, Delmar P, Klingelschmitt G, Yin AY, Spleiss O, Wu L, Shames DS. Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer Whose Tumors Harbor Uncommon Epidermal Growth Factor Receptors Mutations. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26773740 DOI: 10.1016/J.Jtho.2015.12.107 |
0.447 |
|
| 2016 |
Ramalingam SS, O'Byrne K, Boyer M, Mok T, Jänne PA, Zhang H, Liang J, Taylor I, Sbar EI, Paz-Ares L. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26768165 DOI: 10.1093/Annonc/Mdv593 |
0.52 |
|
| 2016 |
Papadimitrakopoulou V, Cappuzzo F, Jotte RM, Reck M, Mok T, Sandler A, Waterkamp D, Coleman S, Sugitani Y, Socinski MA. Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps9103 |
0.412 |
|
| 2016 |
Felip E, Tan DS, Kim D, Mehra R, Orlov S, Park K, Yu C, Mok T, Nishio M, Scagliotti GV, Spigel DR, Sutradhar S, Cesic D, Shaw AT. Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK+) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and -3. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E20520 |
0.41 |
|
| 2016 |
Shaw AT, Janne PA, Besse B, Solomon BJ, Blackhall FH, Camidge DR, Mok T, Hirsh V, Scranton JR, Polli A, Tang Y, Wilner KD, Kim D. Crizotinib vs chemotherapy in ALK+ advanced non-small cell lung cancer (NSCLC): Final survival results from PROFILE 1007. Journal of Clinical Oncology. 34: 9066-9066. DOI: 10.1200/Jco.2016.34.15_Suppl.9066 |
0.544 |
|
| 2016 |
Soria J, Ho SN, Varella-Garcia M, Iafrate AJ, Solomon BJ, Shaw AT, Blackhall FH, Mok T, Wu Y, Pestova E, Siebert FW, Wilner KD, Polli A, Paolini J, Lanzalone S, et al. ALK FISH positivity and crizotinib efficacy in patients (pts) with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 34: 9062-9062. DOI: 10.1200/Jco.2016.34.15_Suppl.9062 |
0.509 |
|
| 2016 |
Lu S, Mok T, Lu Y, Zhou J, Shi Y, Sriuranpong V, Ho JCM, Ong CK, Tsai C, Chung C, Wilner KD, Tang Y, Masters E, Selaru P, Wu Y. Phase 3 study of first-line crizotinib vs pemetrexed−cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 34: 9058-9058. DOI: 10.1200/Jco.2016.34.15_Suppl.9058 |
0.492 |
|
| 2016 |
Hirsh V, Yang JC, Tan E, O'Byrne K, Zhang L, Boyer MJ, Mok T, Lee KH, Lu S, Shi Y, Kim S, Laskin JJ, Kim D, Dubos Arvis C, Kölbeck K, et al. First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). Journal of Clinical Oncology. 34: 9046-9046. DOI: 10.1200/Jco.2016.34.15_Suppl.9046 |
0.51 |
|
| 2016 |
Hirsh V, Park K, Tan E, Zhang L, O'Byrne K, Boyer M, Yang JC, Mok T, Fan J, Massey D, Paz-Ares L. Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) withEGFRmutation-positive (EGFRm+) NSCLC: LUX-Lung 7 European Respiratory Journal. 48. DOI: 10.1183/13993003.Congress-2016.Oa3342 |
0.449 |
|
| 2016 |
Mehra R, Felip E, Tan DS, Kim D, Orlov S, Park K, Yu C, Mok T, Nishio M, Scagliotti GV, Spigel DR, Sutradhar S, Cesic D, Shaw AT. BMET-13. WHOLE BODY AND INTRACRANIAL EFFICACY OF CERITINIB IN ALK-INHIBITOR (ALKi)-NAIVE PATIENTS WITH ALK-REARRANGED (ALK+) NSCLC AND BASELINE BRAIN METASTASES (BM): RESULTS FROM ASCEND-1 AND -3 Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.113 |
0.397 |
|
| 2016 |
Liu S, Reck M, Mok T, Johnson M, Tang X, Lam S, Waterkamp D, Lopez-Chavez A, Sandler A, Giacconne G, Horn L. P3.02c-041 IMpower133: A Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1836 |
0.319 |
|
| 2016 |
Cappuzzo F, Reck M, Papadimitrakopoulou V, Jotte R, West H, Mok T, Sandler A, Mocci S, Coleman S, Asakawa T, Socinski M. P3.02c-038 First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: IT Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1833 |
0.423 |
|
| 2015 |
Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L, Rosell R. Non-small-cell lung cancer. Nature Reviews. Disease Primers. 1: 15009. PMID 27188576 DOI: 10.1038/nrdp.2015.9 |
0.429 |
|
| 2015 |
Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S, Juhász E, Arén O, Sun Y, Schmelter T, Ong TJ, Peña C, ... ... Mok TS, et al. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 1745-53. PMID 26743856 DOI: 10.1097/Jto.0000000000000693 |
0.535 |
|
| 2015 |
Yang JC, Srimuninnimit V, Ahn MJ, Lin CC, Kim SW, Tsai CM, Mok T, Orlando M, Puri T, Wang X, Park K. First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26725183 DOI: 10.1016/J.Jtho.2015.11.008 |
0.568 |
|
| 2015 |
Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong V, Tsai CM, Lee JS, Kang JH, Chan KC, Perez-Moreno P, Button P, Ahn MJ, Mok T. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. Jama Oncology. 1-8. PMID 26720423 DOI: 10.1001/Jamaoncol.2015.4921 |
0.549 |
|
| 2015 |
Mok TS, Loong HH. Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer? Lancet (London, England). PMID 26712085 DOI: 10.1016/S0140-6736(15)01308-2 |
0.36 |
|
| 2015 |
Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S, Juhász E, Arén O, Sun Y, Schmelter T, Ong TJ, Peña C, ... ... Mok TS, et al. MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26551592 DOI: 10.1097/JTO.0000000000000693 |
0.407 |
|
| 2015 |
Li MY, Yuan HL, Ko FW, Wu B, Long X, Du J, Wu J, Ng CS, Wan IY, Mok TS, Hui DS, Underwood MJ, Chen GG. Antineoplastic effects of 15(S)-hydroxyeicosatetraenoic acid and 13-S-hydroxyoctadecadienoic acid in non-small cell lung cancer. Cancer. 121: 3130-45. PMID 26331820 DOI: 10.1002/Cncr.29547 |
0.412 |
|
| 2015 |
Liu SY, Mok T, Wu YL. Novel targeted agents for the treatment of lung cancer in China. Cancer. 121: 3089-96. PMID 26331815 DOI: 10.1002/Cncr.29522 |
0.464 |
|
| 2015 |
Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, ... ... Mok TS, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. The Lancet. Oncology. PMID 26159065 DOI: 10.1016/S1470-2045(15)00121-7 |
0.5 |
|
| 2015 |
Yeung SF, Tong JH, Law PP, Chung LY, Lung RW, Tong CY, Chow C, Chan AW, Wan IY, Mok TS, To KF. Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26098749 DOI: 10.1097/Jto.0000000000000620 |
0.447 |
|
| 2015 |
Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. The Lancet. Oncology. 16: 830-8. PMID 26051236 DOI: 10.1016/S1470-2045(15)00026-1 |
0.429 |
|
| 2015 |
Li MY, Liu Y, Liu LZ, Kong AW, Zhao Z, Wu B, Long X, Wu J, Ng CS, Wan IY, Du J, Mok TS, Underwood MJ, Chen GG. Estrogen receptor alpha promotes smoking-carcinogen-induced lung carcinogenesis via cytochrome P450 1B1. Journal of Molecular Medicine (Berlin, Germany). PMID 26041383 DOI: 10.1007/s00109-015-1300-4 |
0.318 |
|
| 2015 |
Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, Ladrera G, Thongprasert S, Srimuninnimit V, Liao M, Zhu Y, Zhou C, Fuerte F, Margono B, Wen W, et al. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3196-203. PMID 25829397 DOI: 10.1158/1078-0432.CCR-14-2594 |
0.322 |
|
| 2015 |
Loong HH, Mok K, Leung LK, Mok TS. Crizotinib in the management of advanced-stage non-small-cell lung cancer. Future Oncology (London, England). 11: 735-45. PMID 25757678 DOI: 10.2217/Fon.14.314 |
0.505 |
|
| 2015 |
Solomon BJ, Mok T. First-line crizotinib in ALK-positive lung cancer. The New England Journal of Medicine. 372: 782. PMID 25693021 DOI: 10.1056/Nejmc1415973 |
0.442 |
|
| 2015 |
Ng CS, Kim HK, Wong RH, Yim AP, Mok TS, Choi YH. Single-Port Video-Assisted Thoracoscopic Major Lung Resections: Experience with 150 Consecutive Cases. The Thoracic and Cardiovascular Surgeon. PMID 25602850 DOI: 10.1055/s-0034-1396789 |
0.379 |
|
| 2015 |
Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, ... ... Mok T, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet. Oncology. 16: 141-51. PMID 25589191 DOI: 10.1016/S1470-2045(14)71173-8 |
0.532 |
|
| 2015 |
Yatabe Y, Kerr KM, Utomo A, Rajadurai P, Tran VK, Du X, Chou TY, Enriquez ML, Lee GK, Iqbal J, Shuangshoti S, Chung JH, Hagiwara K, Liang Z, Normanno N, ... ... Mok T, et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 438-45. PMID 25376513 DOI: 10.1097/Jto.0000000000000422 |
0.488 |
|
| 2015 |
Camidge DR, Wolf J, Litten JB, Higashi LA, Isaacson JD, Mok T. TIGER 1: A randomized, open-label, phase 2/3 study of rociletinib (CO-1686) or erlotinib as first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps8108 |
0.556 |
|
| 2015 |
Mok T, Wu Y, Watson PA, Zhang J, Rangwala RA, Lopes G. Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 33: TPS8105-TPS8105. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps8105 |
0.455 |
|
| 2015 |
Felip E, Blackhall FH, Mok T, Cappuzzo F, Wilner KD, Reisman A, Iyer S, Solomon BJ. Impact of crizotinib on patient-reported general health status compared with chemotherapy in patients with no prior systemic treatment for advanced non-squamous ALK-positive non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 33: 8101-8101. DOI: 10.1200/Jco.2015.33.15_Suppl.8101 |
0.42 |
|
| 2015 |
Yang JC, Ahn M, Dickgreber NJ, Halmos B, Hirsh V, Hochmair MJ, Levy BP, Marinis FD, Mok T, O'Byrne K, Okamoto I, Schuler MH, Sebastian M, Shah RNH, Tan E, et al. Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 33: 8073-8073. DOI: 10.1200/Jco.2015.33.15_Suppl.8073 |
0.405 |
|
| 2015 |
Lee C, Davies LC, Wu Y, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Throngprasert S, Fukuoka M, Gralla RJ, Gebski V, Mok T, Yang JC. The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials. Journal of Clinical Oncology. 33: 8072-8072. DOI: 10.1200/Jco.2015.33.15_Suppl.8072 |
0.488 |
|
| 2015 |
Felip E, Orlov S, Park K, Yu C, Tsai C, Nishio M, Dols MC, McKeage MJ, Su W, Mok T, Scagliotti GV, Spigel D, Branle F, Emeremni C, Quadrigli M, et al. ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 33: 8060-8060. DOI: 10.1200/Jco.2015.33.15_Suppl.8060 |
0.509 |
|
| 2015 |
Mok T, Spigel D, Felip E, deMarinis F, Ahn M, Groen HJM, Wakelee HA, Hida T, Crino L, Nishio M, Scagliotti GV, Branle F, Emeremni C, Quadrigli M, Zhang J, et al. ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). Journal of Clinical Oncology. 33: 8059-8059. DOI: 10.1200/Jco.2015.33.15_Suppl.8059 |
0.518 |
|
| 2015 |
Yang JC, Srimuninnimit V, Ahn M, Lin C, Kim S, Tsai C, Mok T, Orlando M, Puri T, Wang X, Park K. A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results. Journal of Clinical Oncology. 33: 8041-8041. DOI: 10.1200/Jco.2015.33.15_Suppl.8041 |
0.432 |
|
| 2015 |
Senan S, Brade AM, Wang L, Vansteenkiste JF, Dakhil SR, Biesma B, Aguillo MM, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski CR, Gandara DR, Choy H, Mok T, Hossain A, et al. Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC). Journal of Clinical Oncology. 33: 7506-7506. DOI: 10.1200/Jco.2015.33.15_Suppl.7506 |
0.393 |
|
| 2015 |
Chan SL, Yeo W, Mo F, Li L, Lee KF, Chan AW, Hui EP, Lai PBS, Mok T, Chan ATC, Yu S. A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response. Journal of Clinical Oncology. 33: 4073-4073. DOI: 10.1200/Jco.2015.33.15_Suppl.4073 |
0.334 |
|
| 2014 |
Shaw A, Tan DS, Crinò L, Felip E, Mok TS, Nishio M, Paz-Ares L, Scagliotti G, Spigel DR, Wolf J, Wu Y, Castro G, Sen P, Zheng C, Joe A, et al. 1332TiPTWO PHASE III STUDIES EVALUATING CERITINIB IN PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): ASCEND-4 AND ASCEND-5. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv469. PMID 28171433 DOI: 10.1093/Annonc/Mdu349.111 |
0.478 |
|
| 2014 |
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England Journal of Medicine. 371: 2167-77. PMID 25470694 DOI: 10.1056/Nejmoa1408440 |
0.528 |
|
| 2014 |
Jänne PA, Ou SH, Kim DW, Oxnard GR, Martins R, Kris MG, Dunphy F, Nishio M, O'Connell J, Paweletz C, Taylor I, Zhang H, Goldberg Z, Mok T. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. The Lancet. Oncology. 15: 1433-41. PMID 25456362 DOI: 10.1016/S1470-2045(14)70461-9 |
0.583 |
|
| 2014 |
Ramalingam SS, Jänne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, et al. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. The Lancet. Oncology. 15: 1369-78. PMID 25439691 DOI: 10.1016/S1470-2045(14)70452-8 |
0.55 |
|
| 2014 |
Mok TS. The Yin-Yang of Guidelines and Disparity Oncologist. 19: 1011-1011. PMID 25223464 DOI: 10.1634/Theoncologist.2014-0282 |
0.394 |
|
| 2014 |
Pallaud C, Reck M, Juhasz E, Szima B, Yu CJ, Burdaeva O, Orlov S, Hilton M, Archer V, Mok T. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 86: 67-72. PMID 25154982 DOI: 10.1016/J.Lungcan.2014.07.019 |
0.377 |
|
| 2014 |
Paz-Ares L, Soulières D, Moecks J, Bara I, Mok TS, Klughammer B. Pooled analysis of clinical outcome for EGFR TKI‐treated patients with EGFR mutation‐positive NSCLC Journal of Cellular and Molecular Medicine. 18: 1519-1539. PMID 25100284 DOI: 10.1111/Jcmm.12278 |
0.558 |
|
| 2014 |
Yang JC, Kang JH, Mok T, Ahn MJ, Srimuninnimit V, Lin CC, Kim DW, Tsai CM, Barraclough H, Altug S, Orlando M, Park K. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. European Journal of Cancer (Oxford, England : 1990). 50: 2219-30. PMID 24953333 DOI: 10.1016/J.Ejca.2014.05.011 |
0.572 |
|
| 2014 |
Mok TS, Loong HH. A REVELation in non-small-cell lung cancer treatment? Lancet (London, England). 384: 640-2. PMID 24933331 DOI: 10.1016/S0140-6736(14)60895-3 |
0.471 |
|
| 2014 |
Popat S, Mok T, Yang JCH, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T, Paz-Ares L. Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis Lung Cancer. 85: 230-238. PMID 24929780 DOI: 10.1016/J.Lungcan.2014.05.007 |
0.532 |
|
| 2014 |
Park KS, Raffeld M, Moon YW, Xi L, Bianco C, Pham T, Lee LC, Mitsudomi T, Yatabe Y, Okamoto I, Subramaniam D, Mok T, Rosell R, Luo J, Salomon DS, et al. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. The Journal of Clinical Investigation. 124: 3003-15. PMID 24911146 DOI: 10.1172/Jci73048 |
0.484 |
|
| 2014 |
Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, Benner RJ, Scranton JR, Olszanski AJ, Jassem J. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2059-66. PMID 24888810 DOI: 10.1200/Jco.2013.54.4932 |
0.537 |
|
| 2014 |
Loong HH, Mok TS. Lung cancer: dropping bars or rising hoops--phase III outcomes of NSCLC. Nature Reviews. Clinical Oncology. 11: 381-2. PMID 24840075 DOI: 10.1038/nrclinonc.2014.91 |
0.364 |
|
| 2014 |
Mok TS, Geater SL, Iannotti N, Thongprasert S, Spira A, Smith D, Lee V, Lim WT, Reyderman L, Wang B, Gopalakrishna P, Garzon F, Xu L, Reynolds C. Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 1578-84. PMID 24827127 DOI: 10.1093/Annonc/Mdu174 |
0.534 |
|
| 2014 |
Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Orlov S, Yu CJ, Archer V, Hilton M, Delmar P, Pallaud C, Reck M. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 848-55. PMID 24807156 DOI: 10.1097/Jto.0000000000000160 |
0.438 |
|
| 2014 |
Mok T, Lee K, Tang M, Leung L. Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer. Future Oncology (London, England). 10: 813-22. PMID 24799062 DOI: 10.2217/Fon.14.22 |
0.538 |
|
| 2014 |
Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, O'Byrne K, Stahel R, Peters S, Felip E. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 1681-90. PMID 24718890 DOI: 10.1093/Annonc/Mdu145 |
0.489 |
|
| 2014 |
Mok TS, Lee K, Leung L. Targeting epidermal growth factor receptor in the management of lung cancer. Seminars in Oncology. 41: 101-9. PMID 24565584 DOI: 10.1053/J.Seminoncol.2013.12.010 |
0.545 |
|
| 2014 |
Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer. 15: 173-81. PMID 24486058 DOI: 10.1016/J.Cllc.2013.12.002 |
0.528 |
|
| 2014 |
Yang JJ, Zhang XC, Su J, Xu CR, Zhou Q, Tian HX, Xie Z, Chen HJ, Huang YS, Jiang BY, Wang Z, Wang BC, Yang XN, Zhong WZ, Nie Q, ... ... Mok TS, et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1383-92. PMID 24443522 DOI: 10.1158/1078-0432.Ccr-13-0699 |
0.521 |
|
| 2014 |
Yang JC, Wu YL, Chan V, Kurnianda J, Nakagawa K, Saijo N, Fukuoka M, McWalter G, McCormack R, Mok TS. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer (Amsterdam, Netherlands). 83: 174-81. PMID 24361280 DOI: 10.1016/j.lungcan.2013.11.021 |
0.307 |
|
| 2014 |
Ramalingam SS, Janne PA, Mok T, O'Byrne K, Boyer MJ, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CA, O'Connell JP, Paz-Ares L. Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009). Journal of Clinical Oncology. 32: 8018-8018. DOI: 10.1200/Jco.2014.32.15_Suppl.8018 |
0.556 |
|
| 2014 |
Yang JC, Sequist LV, Schuler MH, Mok T, Yamamoto N, O'Byrne KJ, Hirsh V, Geater SL, Zhou C, Massey D, Zazulina V, Wu Y. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT). Journal of Clinical Oncology. 32: 8004-8004. DOI: 10.1200/Jco.2014.32.15_Suppl.8004 |
0.543 |
|
| 2014 |
Mok T, Kim D, Wu Y, Solomon BJ, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tursi J, Blackhall FH. First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014) Journal of Clinical Oncology. 32: 8002-8002. DOI: 10.1200/Jco.2014.32.15_Suppl.8002 |
0.557 |
|
| 2014 |
Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Shames DS, Yu W, Paton VE, Mok T. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. Journal of Clinical Oncology. 32: 8000-8000. DOI: 10.1200/Jco.2014.32.15_Suppl.8000 |
0.389 |
|
| 2014 |
Nakagawa K, Kim D, Wu Y, Solomon BJ, Mekhail T, Felip E, Cappuzzo F, Blackhall F, Usari T, Mok T. Ps-1First-Line Crizotinib Vs Pemetrexed + Cisplatin/Carboplatin In Asian Patients With Advanced Alk+ Nsclc In Profile 1014 Annals of Oncology. 25. DOI: 10.1093/Annonc/Mdu395.1 |
0.426 |
|
| 2014 |
Wu Y, Sequist L, Hu C, Feng J, Lu S, Huang Y, Li W, Hou M, Schuler M, Mok T, Yamamoto N, O'Byrne K, Hirsh V, Gibson N, Massey D, et al. Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Circulating Cell-Free DNA in Two Phase III Studies (LUX-Lung 3 and LUX-Lung 6) of Afatinib vs Platinum-Based Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer American Journal of Clinical Pathology. 142: A182-A182. DOI: 10.1093/Ajcp/142.Suppl1.182 |
0.55 |
|
| 2014 |
Yang J, Park K, Mok T, Kang J, Srimuninnimit V, Lin C, Kim D, Tsai C, Orlando M, Nair R. P0066 A randomised phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer European Journal of Cancer. 50: e27. DOI: 10.1016/J.Ejca.2014.03.110 |
0.576 |
|
| 2013 |
Huang RY, Li MY, Ng CS, Wan IY, Kong AW, Du J, Long X, Underwood MJ, Mok TS, Chen GG. Thromboxane A2 receptor α promotes tumor growth through an autoregulatory feedback pathway. Journal of Molecular Cell Biology. 5: 380-90. PMID 24115277 DOI: 10.1093/jmcb/mjt038 |
0.304 |
|
| 2013 |
Mok TS, Wu YL. Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC? - authors' reply. The Lancet. Oncology. 14: e438-9. PMID 24079868 DOI: 10.1016/S1470-2045(13)70434-0 |
0.468 |
|
| 2013 |
Zhang XC, Lu S, Zhang L, Wang CL, Cheng Y, Li GD, Mok T, Huang C, Liu XQ, Wang J, Wang MZ, Zhang YP, Zhou JY, Zhou XY, Lin DM, et al. [Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version]. Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology. 42: 402-6. PMID 24060077 DOI: 10.3760/Cma.J.Issn.0529-5807.2013.06.012 |
0.527 |
|
| 2013 |
Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. The Lancet. 382: 709-719. PMID 23972814 DOI: 10.1016/S0140-6736(13)61502-0 |
0.481 |
|
| 2013 |
Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3342-50. PMID 23816967 DOI: 10.1200/Jco.2012.46.1764 |
0.489 |
|
| 2013 |
Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3327-34. PMID 23816960 DOI: 10.1200/Jco.2012.44.2806 |
0.528 |
|
| 2013 |
Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, ... ... Mok T, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. The Lancet. Oncology. 14: 777-86. PMID 23782814 DOI: 10.1016/S1470-2045(13)70254-7 |
0.551 |
|
| 2013 |
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, ... Mok T, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. The New England Journal of Medicine. 368: 2385-94. PMID 23724913 DOI: 10.1056/Nejmoa1214886 |
0.523 |
|
| 2013 |
To KF, Tong JH, Yeung KS, Lung RW, Law PP, Chau SL, Kang W, Tong CY, Chow C, Chan AW, Leung LK, Mok TS. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 883-91. PMID 23625156 DOI: 10.1097/JTO.0b013e3182904e22 |
0.331 |
|
| 2013 |
Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, Nieva J, Novello S, Ou SHI, Camidge DR. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients Cancer. 119: 2383-2390. PMID 23585220 DOI: 10.1002/Cncr.28089 |
0.328 |
|
| 2013 |
Wu YL, Fukuoka M, Mok TS, Saijo N, Thongprasert S, Yang JC, Chu DT, Yang JJ, Rukazenkov Y. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. Lung Cancer (Amsterdam, Netherlands). 81: 280-7. PMID 23540718 DOI: 10.1016/j.lungcan.2013.03.004 |
0.395 |
|
| 2013 |
Mok T, Yang JJ, Lam KC. Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1081-8. PMID 23401448 DOI: 10.1200/Jco.2012.43.0652 |
0.504 |
|
| 2013 |
Hirsch FR, Jänne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS. Epidermal growth factor receptor inhibition in lung cancer: status 2012. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 373-84. PMID 23370315 DOI: 10.1097/Jto.0B013E31827Ed0Ff |
0.577 |
|
| 2013 |
Langer CJ, Mok T, Postmus PE. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treatment Reviews. 39: 252-260. PMID 22703830 DOI: 10.1016/J.Ctrv.2012.05.003 |
0.484 |
|
| 2013 |
Boyer M, Jänne PA, Mok T, O’Byrne K, Paz-Ares L, Ramalingam SS, Liang J, Taylor I, Campbell A, O’Connell J, Letrent S, Antic V. Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer Clinical Investigation. 3: 29-35. DOI: 10.4155/Cli.12.137 |
0.56 |
|
| 2013 |
Mok T, Nakagawa K, Rosell R, Wu YL, Trygstad C, Capizzi RL, Lee MY, Tsuji F, DeBenedetto R, Goldberg Z, Wang T, Liang JQ, Letrent SP, O'Connell JP, Antic V. Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (EGFR) activating mutation(s). Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps8123 |
0.508 |
|
| 2013 |
Shaw AT, Mok T, Spigel DR, Nishio M, Felip E, Tan DS, Garcia-Campelo MR, Groen HJM, Dakhil SR, Schaefer ES, Farrell NJ, Blakesley RE, Weir A, Ristic M, Selvaggi G, et al. A phase II single-arm study of LDK378 in patients with ALK-activated (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps8119 |
0.504 |
|
| 2013 |
Mok T, Wu YL, Lee JS, Yu C, Sriuranpong V, Wen W, Tsai J, Truman M, Klughammer B, Wu L. Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: A randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C). Journal of Clinical Oncology. 31: 8021-8021. DOI: 10.1200/Jco.2013.31.15_Suppl.8021 |
0.435 |
|
| 2013 |
Park K, Giuseppe G, Wang Y, Pham T, Moon Y, Luo J, Lee LC, Mitsudomi T, Okamoto I, Yatabe Y, Mok T, Raffeld M, Xi L, Salomon DS, Bianco C. Abstract 4468: Cripto-1 elicits innate resistance to EGFR inhibitors in non-small cell lung cancer harboring EGFR-sensitizing mutations. Cancer Research. 73: 4468-4468. DOI: 10.1158/1538-7445.Am2013-4468 |
0.527 |
|
| 2012 |
Mok TS, Zhou Q, Wu YL. Research and standard care: lung cancer in china. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 432-6. PMID 24451776 DOI: 10.14694/EdBook_AM.2012.32.432 |
0.396 |
|
| 2012 |
Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, Rittweger K, Thurm H. Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 13: 500-4. PMID 23063071 DOI: 10.1016/J.Cllc.2012.05.009 |
0.52 |
|
| 2012 |
Leung L, Lam KC, Mok TS. Non-small cell lung cancer: One size doesn't fit all. Asia-Pacific Journal of Clinical Oncology. 8: 211-2. PMID 22913780 DOI: 10.1111/j.1743-7563.2012.01587.x |
0.309 |
|
| 2012 |
Wu YL, Chu DT, Han B, Liu X, Zhang L, Zhou C, Liao M, Mok T, Jiang H, Duffield E, Fukuoka M. Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: Evaluation of patients recruited from mainland China Asia-Pacific Journal of Clinical Oncology. 8: 232-243. PMID 22897752 DOI: 10.1111/J.1743-7563.2012.01518.X |
0.483 |
|
| 2012 |
An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ, Yang JJ, Zhou Q, Yang XN, Huang L, Guan JL, Nie Q, Yan HH, Mok TS, Wu YL. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. Plos One. 7: e40109. PMID 22768234 DOI: 10.1371/Journal.Pone.0040109 |
0.467 |
|
| 2012 |
Leung L, Mok TS, Loong H. Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 4: 173-81. PMID 22754591 DOI: 10.1177/1758834012440015 |
0.403 |
|
| 2012 |
Mok TS, D'arcangelo M, Califano R. Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation. Drugs. 72: 3-10. PMID 22712792 DOI: 10.2165/1163014-S0-000000000-00000 |
0.537 |
|
| 2012 |
Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, Yang JJ, Zhou Q, Yan HH, An SJ, Chen HJ, Jiang BY, Mok TS, Wu YL. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. The Oncologist. 17: 978-85. PMID 22673630 DOI: 10.1634/Theoncologist.2011-0385 |
0.506 |
|
| 2012 |
Soo RA, Kawaguchi T, Loh M, Ou SH, Shieh MP, Cho BC, Mok TS, Soong R. Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. Future Oncology (London, England). 8: 451-62. PMID 22515448 DOI: 10.2217/Fon.12.25 |
0.493 |
|
| 2012 |
Mitchell P, Mok TS, Barraclough H, Strizek A, Lew R, Kooten MV. Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: a systematic review. Clinical Lung Cancer. 13: 239-251. PMID 22154074 DOI: 10.1016/J.Cllc.2011.08.003 |
0.442 |
|
| 2012 |
Soria JC, Mok TS, Cappuzzo F, Jänne PA. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treatment Reviews. 38: 416-30. PMID 22119437 DOI: 10.1016/J.Ctrv.2011.10.003 |
0.55 |
|
| 2012 |
Chan SL, Mo FK, Wong VW, Liem GS, Wong GL, Chan VT, Poon DM, Loong HH, Yeo W, Chan AT, Mok TS, Chan HL. Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. Liver International : Official Journal of the International Association For the Study of the Liver. 32: 271-8. PMID 22098536 DOI: 10.1111/J.1478-3231.2011.02634.X |
0.324 |
|
| 2012 |
Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, Itoh Y, Jiang H, Duffield E, McCormack R, Saijo N, Mok T, Fukuoka M. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 115-21. PMID 21900837 DOI: 10.1097/Jto.0B013E3182307F98 |
0.47 |
|
| 2012 |
de Lima Lopes G, Segel JE, Tan DS, Do YK, Mok T, Finkelstein EA. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer. 118: 1032-9. PMID 21792863 DOI: 10.1002/Cncr.26372 |
0.46 |
|
| 2012 |
Kim GP, Mahoney MR, Szydlo D, Mok TS, Marshke R, Holen K, Picus J, Boyer M, Pitot HC, Rubin J, Philip PA, Nowak A, Wright JJ, Erlichman C. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Investigational New Drugs. 30: 387-94. PMID 20839030 DOI: 10.1007/S10637-010-9532-1 |
0.4 |
|
| 2012 |
Satouchi M, Ichinose Y, Nishiwaki Y, Ohe Y, Yamamoto N, Katakami N, Nakagawa K, Kiura K, Jiang H, Mok T, Saijo N, Fukuoka M. Final analysis of overall survival (OS) in the IPASS, an international multicenter phase III study on gefitinib and carboplatin/paclitaxel for treatment-naïve NSCLC patients Japanese Journal of Lung Cancer. 52: 153-160. DOI: 10.2482/Haigan.52.153 |
0.464 |
|
| 2012 |
Spigel DR, Edelman MJ, Mok T, O'Byrne KJ, Paz-Ares L, Yu W, Rittweger K, Thurm HC. The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps7616 |
0.463 |
|
| 2012 |
Boyer MJ, Janne PA, Mok T, O'Byrne KJ, Paz-Ares LG, Ramalingam SS, Liang JQ, Taylor I, Campbell A, O'Connell JP, Letrent SP, Antic V. ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase III study. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps7615 |
0.488 |
|
| 2012 |
Park K, Tsai C, Ahn M, Yu C, Kim S, Sriuranpong V, Kuo HP, Lee J, Kang JH, Lin M, Geater SL, Chang G, Seetalarom K, So PFP, Lai R, ... ... Mok T, et al. ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps7614 |
0.535 |
|
| 2012 |
Yang JC, Schuler MH, Yamamoto N, O'Byrne KJ, Hirsh V, Mok T, Geater SL, Orlov SV, Tsai C, Boyer MJ, Su W, Bennouna J, Kato T, Gorbunova V, Lee KH, et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Lba7500 |
0.538 |
|
| 2012 |
Kris MG, Mok T, Ou SI, Martins R, Kim D, Goldberg Z, Zhang H, Taylor I, Letrent SP, Janne PA. First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers. Journal of Clinical Oncology. 30: 7530-7530. DOI: 10.1200/Jco.2012.30.15_Suppl.7530 |
0.541 |
|
| 2012 |
Mok T, Wu YL, Thongprasert S, Yu C, Zhang L, Ladrera GE, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen Y, et al. A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II. Journal of Clinical Oncology. 30: 7519-7519. DOI: 10.1200/Jco.2012.30.15_Suppl.7519 |
0.53 |
|
| 2012 |
An S, Chen Z, Su J, Zhang X, Zhong W, Yang J, Zhou Q, Yang X, Huang L, Guan J, Nie Q, Yan H, Mok TS, Wu Y. Abstract 4573: Enriched driver genes based on histology and smoking status in Asian patients with non-small cell lung cancer Cancer Research. 72: 4573-4573. DOI: 10.1158/1538-7445.Am2012-4573 |
0.438 |
|
| 2012 |
Kris MG, Mok T, Ou S-I, Martins RG, Kim D-, Goldberg Z, Zhang H, Taylor I, Letrent SP, Jänne PA. First-Line Dacomitinib (PF-00299804), an Irreversible Pan-Her Tyrosine Kinase Inhibitor, for Patients with EGFR-Mutant Lung Cancers Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)32010-X |
0.545 |
|
| 2012 |
Schuler M, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, Massey D, Zazulina V, Shahidi M, Sequist L. LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations Lung Cancer. 77. DOI: 10.1016/J.Lungcan.2012.05.043 |
0.539 |
|
| 2012 |
Loong HH, Wei J, Mok TS. Ethnic variation in response to EGFR inhibitors Drug Discovery Today: Therapeutic Strategies. 9. DOI: 10.1016/J.Ddstr.2011.04.003 |
0.524 |
|
| 2011 |
Wang ZJ, An TT, Mok T, Yang L, Bai H, Zhao J, Duan JC, Wu MN, Wang YY, Li PP, Sun H, Yang P, Wang J. Immediate Versus Delayed Treatment with EGFR Tyrosine Kinase Inhibitors after First-line Therapy in Advanced Non-small-cell Lung CANCER. Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu. 23: 112-7. PMID 23483659 DOI: 10.1007/S11670-011-0112-5 |
0.462 |
|
| 2011 |
Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, Ely G, Yang JC, Mok T. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. Bmc Cancer. 11: 430. PMID 21982342 DOI: 10.1186/1471-2407-11-430 |
0.527 |
|
| 2011 |
Mok TS. Personalized medicine in lung cancer: what we need to know. Nature Reviews. Clinical Oncology. 8: 661-8. PMID 21862980 DOI: 10.1038/Nrclinonc.2011.126 |
0.518 |
|
| 2011 |
Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, ... ... Mok TS, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2866-74. PMID 21670455 DOI: 10.1200/Jco.2010.33.4235 |
0.556 |
|
| 2011 |
Mok TS, Lam KC. The diverse diversity. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 842-3. PMID 21623264 DOI: 10.1097/Jto.0B013E31821972Ed |
0.511 |
|
| 2011 |
Mok TS, Hsia TC, Tsai CM, Tsang K, Chang GC, Chang JW, Sirisinha T, Thitiya S, Sriuranpong V, Thongprasert S, Chua DT, Moore N, Manegold C. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial. Asia-Pacific Journal of Clinical Oncology. 7: 4-12. PMID 21585703 DOI: 10.1111/J.1743-7563.2011.01397.X |
0.488 |
|
| 2011 |
Mok TS. Bevacizumab in the treatment of non-small cell lung cancer: focus on East Asia. Asia-Pacific Journal of Clinical Oncology. 7: 1-3. PMID 21585702 DOI: 10.1111/J.1743-7563.2011.01401.X |
0.478 |
|
| 2011 |
Soo RA, Loh M, Mok TS, Ou SH, Cho BC, Yeo WL, Tenen DG, Soong R. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1030-8. PMID 21532500 DOI: 10.1097/Jto.0B013E3182199C03 |
0.473 |
|
| 2011 |
Lee YJ, Kim JH, Kim SK, Ha SJ, Mok TS, Mitsudomi T, Cho BC. Lung cancer in never smokers: change of a mindset in the molecular era. Lung Cancer (Amsterdam, Netherlands). 72: 9-15. PMID 21272954 DOI: 10.1016/J.Lungcan.2010.12.013 |
0.503 |
|
| 2011 |
Chan SL, Mo FK, Johnson PJ, Liem GS, Chan TC, Poon MC, Ma BB, Leung TW, Lai PB, Chan AT, Mok TS, Yeo W. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. Journal of Gastroenterology and Hepatology. 26: 340-7. PMID 21261725 DOI: 10.1111/J.1440-1746.2010.06329.X |
0.334 |
|
| 2011 |
Gridelli C, Marinis FD, Maio MD, Cortinovis D, Cappuzzo F, Mok TS. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence Lung Cancer. 71: 249-257. PMID 21216486 DOI: 10.1016/J.Lungcan.2010.12.008 |
0.576 |
|
| 2011 |
Reck M, Mok TS, Wolf J, Heigener D, Wu YL. Reviewing the safety of erlotinib in non-small cell lung cancer. Expert Opinion On Drug Safety. 10: 147-157. PMID 21138395 DOI: 10.1517/14740338.2011.540799 |
0.542 |
|
| 2011 |
Lam KC, Mok TS. Targeted therapy: an evolving world of lung cancer. Respirology (Carlton, Vic.). 16: 13-21. PMID 20723139 DOI: 10.1111/J.1440-1843.2010.01821.X |
0.544 |
|
| 2011 |
Lui VW, Lau CP, Ho K, Ng MH, Cheng SH, Tsao SW, Tsang CM, Lei KI, Chan AT, Mok TS. Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. Investigational New Drugs. 29: 1241-52. PMID 20571878 DOI: 10.1007/S10637-010-9470-Y |
0.438 |
|
| 2011 |
Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Yu CJ, Delmar P, Pallaud C, Jonnaert M, Reck M. 9003 ORAL Biomarker Analysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatin-gemcitabine (CG) or Carboplatin-paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC) European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)72315-2 |
0.544 |
|
| 2010 |
Mok TS, Zhou Q, Leung L, Loong HH. Personalized medicine for non-small-cell lung cancer. Expert Review of Anticancer Therapy. 10: 1601-11. PMID 20942631 DOI: 10.1586/Era.10.76 |
0.545 |
|
| 2010 |
Saijo N, Fukuoka M, Thongprasert S, Ichinose Y, Mitsudomi T, Mok TS, Ohe Y, Park K, Wu YL. Lung cancer working group report. Japanese Journal of Clinical Oncology. 40: i7-12. PMID 20870923 DOI: 10.1093/jjco/hyq121 |
0.398 |
|
| 2010 |
Mok T, Wu YL, Au JS, Zhou C, Zhang L, Perng RP, Park K. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 1609-15. PMID 20808255 DOI: 10.1097/Jto.0B013E3181E15D55 |
0.554 |
|
| 2010 |
Leung KC, Li MY, Leung BC, Hsin MK, Mok TS, Underwood MJ, Chen GG. Thromboxane synthase suppression induces lung cancer cell apoptosis via inhibiting NF-κB. Experimental Cell Research. 316: 3468-77. PMID 20647010 DOI: 10.1016/J.Yexcr.2010.07.003 |
0.355 |
|
| 2010 |
Lin CC, Hsu HH, Sun CT, Shih JY, Lin ZZ, Yu CJ, Chen GG, Hsin MK, Lam KC, Leung L, Yang CH, Mok T. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 1424-9. PMID 20631634 DOI: 10.1097/Jto.0B013E3181E9Db73 |
0.545 |
|
| 2010 |
Zhong WZ, Wu YL, Yang XN, Guo AL, Su J, Zhang XC, Luo DL, Wang Z, Chen HJ, Zhou Q, Xu CR, Qiao GB, Liao RQ, Yang JJ, Mok TS. Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component. Clinical Lung Cancer. 11: 160-8. PMID 20439191 DOI: 10.3816/Clc.2010.N.020 |
0.477 |
|
| 2010 |
Mok TS. A target or a demi-target. Clinical Lung Cancer. 11: 147-8. PMID 20439189 DOI: 10.3816/Clc.2010.N.018 |
0.481 |
|
| 2010 |
Yuan H, Li MY, Ma LT, Hsin MK, Mok TS, Underwood MJ, Chen GG. 15-Lipoxygenases and its metabolites 15(S)-HETE and 13(S)-HODE in the development of non-small cell lung cancer. Thorax. 65: 321-6. PMID 20388757 DOI: 10.1136/Thx.2009.122747 |
0.407 |
|
| 2010 |
Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 17: 77-88. PMID 20129249 DOI: 10.1016/J.Ccr.2009.11.022 |
0.515 |
|
| 2010 |
Ma BB, Hui EP, Mok TS. Population-based differences in treatment outcome following anticancer drug therapies. The Lancet. Oncology. 11: 75-84. PMID 20129130 DOI: 10.1016/S1470-2045(09)70160-3 |
0.407 |
|
| 2010 |
Mok T, Wu YL, Zhang L. A small step towards personalized medicine for non-small cell lung cancer. Discovery Medicine. 8: 227-31. PMID 20040275 |
0.514 |
|
| 2010 |
Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV, Watkins CL, Speake G, Armour AA, Kim ES. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 744-52. PMID 20038723 DOI: 10.1200/Jco.2009.24.3030 |
0.568 |
|
| 2010 |
Paz-Ares L, Soulières D, Melezínek I, Moecks J, Keil L, Mok T, Rosell R, Klughammer B. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis Journal of Cellular and Molecular Medicine. 14: 51-69. PMID 20015198 DOI: 10.1111/J.1582-4934.2009.00991.X |
0.547 |
|
| 2009 |
Soo RA, Anderson BO, Cho BC, Yang CH, Liao M, Lim WT, Goldstraw P, Mok TS. First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. The Lancet. Oncology. 10: 1102-10. PMID 19880064 DOI: 10.1016/S1470-2045(09)70238-4 |
0.429 |
|
| 2009 |
Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, Ignacio J, Liao M, Srimuninnimit V, Boyer MJ, Chua-Tan M, Sriuranpong V, Sudoyo AW, Jin K, Johnston M, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5080-7. PMID 19738125 DOI: 10.1200/Jco.2008.21.5541 |
0.474 |
|
| 2009 |
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine. 361: 947-57. PMID 19692680 DOI: 10.1056/Nejmoa0810699 |
0.483 |
|
| 2009 |
Mok TS, Ramalingam SS. Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm. Cancer. 115: 5143-54. PMID 19658185 DOI: 10.1002/cncr.24563 |
0.331 |
|
| 2009 |
Leung KC, Hsin MK, Chan JS, Yip JH, Li M, Leung BC, Mok TS, Warner TD, Underwood MJ, Chen GG. Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27. Experimental Cell Research. 315: 2974-81. PMID 19576211 DOI: 10.1016/J.Yexcr.2009.06.025 |
0.412 |
|
| 2009 |
Chen HJ, Mok TS, Chen ZH, Guo AL, Zhang XC, Su J, Wu YL. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathology Oncology Research : Por. 15: 651-8. PMID 19381876 DOI: 10.1007/S12253-009-9167-8 |
0.506 |
|
| 2009 |
Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2076-84. PMID 19276259 DOI: 10.1158/1078-0432.CCR-08-2622 |
0.369 |
|
| 2009 |
Azim HA, Elattar I, Loberiza FR, Azim H, Mok T, Ganti AK. Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: A systematic overview Lung Cancer. 64: 194-198. PMID 18809226 DOI: 10.1016/J.Lungcan.2008.08.011 |
0.483 |
|
| 2009 |
Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Research and Treatment. 113: 529-35. PMID 18327706 DOI: 10.1007/S10549-008-9957-9 |
0.376 |
|
| 2009 |
MOK T, YANG T, CHAO Y, WANG C, LIU M, KANG YK, KANG WK, KIM JS, WANG Y, LEUNG T. Phase II study of irinotecan in combination with capecitabine as a first-line chemotherapy in Asian patients with inoperable hepatocellular carcinoma Asia-Pacific Journal of Clinical Oncology. 5: 95-100. DOI: 10.1111/J.1743-7563.2009.01198.X |
0.412 |
|
| 2008 |
Zhu J, Wu Y, Zhong W, Zhang G, Li R, Zhang X, Guo A, Zhang Y, An S, Mok TS. Better survival with epidermal growth factor receptor exon 19 deletion than with exon 21 mutation in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 14501. PMID 27950796 DOI: 10.1200/Jco.2008.26.15_Suppl.14501 |
0.525 |
|
| 2008 |
Lee JS, Ignacio J, Yu C, Zhou C, Wu Y, Chen Y, Zhang L, Jin K, Johnston M, Mok TS. FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 8031. PMID 27949057 DOI: 10.1200/Jco.2008.26.15_Suppl.8031 |
0.519 |
|
| 2008 |
Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (London, England). 372: 1809-18. PMID 19027483 DOI: 10.1016/S0140-6736(08)61758-4 |
0.569 |
|
| 2008 |
Li R, An SJ, Chen ZH, Zhang GC, Zhu JQ, Nie Q, Xie Z, Guo AL, Mok TS, Wu YL. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. Human Pathology. 39: 1792-801. PMID 18715616 DOI: 10.1016/J.Humpath.2008.05.008 |
0.421 |
|
| 2008 |
Azim HA, Mok T. Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life. Anti-Cancer Drugs. 19: 645-653. PMID 18525325 DOI: 10.1097/Cad.0B013E3282Ff0F48 |
0.316 |
|
| 2008 |
Li MY, Yip J, Hsin MKY, Mok TS, Wu Y, Underwood MJ, Chen GG. Haem oxygenase-1 plays a central role in NNK-mediated lung carcinogenesis European Respiratory Journal. 32: 911-923. PMID 18508827 DOI: 10.1183/09031936.00064508 |
0.433 |
|
| 2008 |
Zhu JQ, Zhong WZ, Zhang GC, Li R, Zhang XC, Guo AL, Zhang YF, An SJ, Mok TS, Wu YL. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Letters. 265: 307-17. PMID 18407408 DOI: 10.1016/J.Canlet.2008.02.064 |
0.524 |
|
| 2008 |
Mok TS, Crowley J. Big question, small answer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: 105-6. PMID 18303427 DOI: 10.1097/Jto.0B013E31816432Bc |
0.417 |
|
| 2008 |
Ma B, Goh BC, Tan EH, Lam KC, Soo R, Leong SS, Wang LZ, Mo F, Chan AT, Zee B, Mok T. A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Investigational New Drugs. 26: 169-73. PMID 17851637 DOI: 10.1007/S10637-007-9085-0 |
0.485 |
|
| 2008 |
Ma B, Hui EP, King A, To KF, Mo F, Leung SF, Kam M, Lo YM, Zee B, Mok T, Ahuja A, Chan AT. A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer Chemotherapy and Pharmacology. 62: 59-64. PMID 17762933 DOI: 10.1007/S00280-007-0575-8 |
0.382 |
|
| 2008 |
Douillard J, Hirsh V, Mok TS, Socinski MA, Watkins C, Lowe E, Armour A, Kim ES. Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST) Journal of Clinical Oncology. 26: 8001-8001. DOI: 10.1200/Jco.2008.26.15_Suppl.8001 |
0.516 |
|
| 2007 |
Mok TS, Ho S, Chan G, Ho WM, Wong H, Chan AT, Yeo W, Yim AP, Chak K, Lee Y, Lam KC. Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 2: 838-44. PMID 17805062 DOI: 10.1097/JTO.0b013e3181461976 |
0.452 |
|
| 2007 |
Nie Q, Wang Z, Zhang GC, An SJ, Lin JY, Guo AL, Li R, Gan B, Huang Y, Mok TS, Wu YL. The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib. European Journal of Pharmacology. 570: 175-81. PMID 17597605 DOI: 10.1016/J.Ejphar.2007.05.015 |
0.428 |
|
| 2007 |
An SJ, Nie Q, Chen ZH, Lin QX, Wang Z, Xie Z, Chen SL, Huang Y, Zhang AY, Yan JF, Wu HS, Lin JY, Li R, Zhang XC, Guo AL, ... Mok TS, et al. KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer. Journal of Cancer Research and Clinical Oncology. 133: 635-42. PMID 17479290 DOI: 10.1007/S00432-007-0214-0 |
0.45 |
|
| 2007 |
Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, Zhou Q, Xu CR, Wang Z, Zhang GC, Mok T. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 2: 430-9. PMID 17473659 DOI: 10.1097/01.Jto.0000268677.87496.4C |
0.532 |
|
| 2007 |
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (New York, N.Y.). 316: 1039-43. PMID 17463250 DOI: 10.1126/Science.1141478 |
0.486 |
|
| 2007 |
Mok T, Lui P, Lam KC, Yim A, Wan I, Lee S, Hsin M, Leung L, To K. Novel mutations and mutation pattern of epidermal growth factor receptor (EGFR) gene in Chinese patients with primary lung adenocarcinoma Journal of Clinical Oncology. 25: 7667-7667. DOI: 10.1200/Jco.2007.25.18_Suppl.7667 |
0.407 |
|
| 2007 |
Lee S, Mok T, Li H, Yim A, Wan I, Lam KC, Chan A, To KF, Tao Q. Possible correlation between SOCS1 methylation and EGFR exon 19 mutation but not exon 21 mutation in Chinese NSCLC patients Journal of Clinical Oncology. 25: 18113-18113. DOI: 10.1200/Jco.2007.25.18_Suppl.18113 |
0.426 |
|
| 2007 |
Mok TS, Choi E, Wong C, Leung L, Lui P, To KF, Lam KC, Lui V. P2-046: To overcome T790M associated EGFR TKI resistance by addition of mono-clonal antibodies against HER-1 and/or HER-2 receptors Journal of Thoracic Oncology. 2: S508. DOI: 10.1097/01.Jto.0000283510.13549.A8 |
0.338 |
|
| 2007 |
Douillard J, Kim E, Hirsh V, Mok T, Socinski M, Gervais R, Wu Y, Li L, Sellers M, Lowe E. PRS-02: Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST) Journal of Thoracic Oncology. 2. DOI: 10.1097/01.Jto.0000283087.71346.19 |
0.544 |
|
| 2007 |
Mok TS. MTP23-01: Salvage therapy for NSCLC Journal of Thoracic Oncology. 2. DOI: 10.1097/01.Jto.0000283064.56945.B1 |
0.376 |
|
| 2006 |
Abratt RP, Lee JS, Han JY, Tsai CM, Boyer M, Mok T, Kim SW, Brnabic AJM, Reece WHH, Lehnert M. Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer Journal of Thoracic Oncology. 1: 135-140. PMID 17409842 DOI: 10.1097/01243894-200602000-00006 |
0.416 |
|
| 2006 |
Chen GG, Lee TW, Yip JH, Xu H, Lee IK, Mok TS, Warner TD, Yim AP. Increased thromboxane B(2) levels are associated with lipid peroxidation and Bcl-2 expression in human lung carcinoma. Cancer Letters. 234: 193-8. PMID 15876485 DOI: 10.1016/J.Canlet.2005.03.032 |
0.37 |
|
| 2006 |
Bergqvist M, Sörenson S, Brattström D, Mok TS, Henriksson R. Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer American Journal of Cancer. 5: 223-244. DOI: 10.2165/00024669-200605040-00003 |
0.452 |
|
| 2006 |
Chan AT, Ma B, Hui EP, King A, Kam M, Kwan WH, Mok T, Leung SF. Phase II study of gefitinib in metastatic or locoregionally recurrent nasopharyngeal carcinoma (NPC) Journal of Clinical Oncology. 24: 15509-15509. DOI: 10.1200/Jco.2006.24.18_Suppl.15509 |
0.438 |
|
| 2006 |
Abratt RP, Lee JS, Han JY, Tsai CM, Boyer M, Mok TS, Kim SW, Lee JS, Brnabic AJM, Reece WHH, Lehnert M. Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer Journal of Thoracic Oncology. 1: 135-140. DOI: 10.1016/S1556-0864(15)31528-8 |
0.494 |
|
| 2006 |
Chen GG, Li M, Lee TW, Mok TS, Yim AP. Induction of apoptosis by troglitazone requires peroxisome proliferator-activated receptor gamma and ERK in lung cancer cells Developmental Biology. 295: 436. DOI: 10.1016/J.Ydbio.2006.04.341 |
0.405 |
|
| 2005 |
Abratt RP, Lee JS, Han JY, Tsai CM, Boyer M, Mok T, Kim SW, Lee JS, Brnabic AJ, Lehnert M. Phase II trial of gemcitabine-carboplatin-paclitaxel (GCP) as neo-adjuvant chemotherapy for operable non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7260. PMID 27945480 DOI: 10.1200/Jco.2005.23.16_Suppl.7260 |
0.479 |
|
| 2005 |
Posey J, Johnson P, Mok T, Hirmand M, Dahlberg S, Kwei L, Leung T. Results of a phase 2/3 open-label, randomized trial of T138067 versus doxorubicin (DOX) in chemotherapy-naïve, unresectable hepatocellular carcinoma (HCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4035. PMID 27944134 DOI: 10.1200/Jco.2005.23.16_Suppl.4035 |
0.306 |
|
| 2005 |
Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. Journal of the National Cancer Institute. 97: 1532-8. PMID 16234567 DOI: 10.1093/Jnci/Dji315 |
0.381 |
|
| 2005 |
Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5878-85. PMID 16115929 DOI: 10.1158/1078-0432.Ccr-04-2618 |
0.433 |
|
| 2005 |
Ho WM, Ma B, Mok T, Yeo W, Lai P, Lim R, Koh J, Wong YY, King A, Leow CK, Chan AT. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. Medical Oncology (Northwood, London, England). 22: 303-12. PMID 16110141 DOI: 10.1385/Mo:22:3:303 |
0.381 |
|
| 2005 |
Yeo W, Hui EP, Chan AT, Ho WM, Lam KC, Chan PK, Mok TS, Lee JJ, Mo FK, Johnson PJ. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. American Journal of Clinical Oncology. 28: 379-84. PMID 16062080 DOI: 10.1097/01.Coc.0000159554.97885.88 |
0.327 |
|
| 2005 |
Mok TS, Lam KC, Lee C, Zhang L, Wong H, Chan AT, Yeo W, Yim AP, Chak K, Zee B. Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer. Oncology. 68: 485-92. PMID 16020979 DOI: 10.1159/000086992 |
0.364 |
|
| 2005 |
Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, Hui EP, Yiu HY, Yeo W, Cheung FY, Yu KH, Chiu KW, Chan DT, Mok TS, Yau S, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. Journal of the National Cancer Institute. 97: 536-9. PMID 15812080 DOI: 10.1093/Jnci/Dji084 |
0.367 |
|
| 2005 |
Mok T, Wong C, Lam K, Chan L, Pan Z, Au W, Xu M, Chan A, Chak K, Zee B. P-832 Chinese herbal medicine (CHM) induces immuno-modulation in patients with advanced stage non-small lung cancer (NSCLC): A double-blind placebo-control randomized study Lung Cancer. 49: S338-S339. DOI: 10.1016/S0169-5002(05)81325-X |
0.505 |
|
| 2005 |
Abratt R, Lee J, Han J, Tsai C, Boyer M, Mok T, Kim S, Brnabic A, Lehnert M. PD-084 Phase II trial of gemcitabine-carboplatin-paclitaxel (GCP) as neo-adjuvant chemotherapy for operable non-small cell lung cancer (NSCLC) Lung Cancer. 49. DOI: 10.1016/S0169-5002(05)80417-9 |
0.477 |
|
| 2004 |
Mok T. A new horizon of targeted therapy in management of lung cancer Chinese Journal of Lung Cancer. 7: 276-283. PMID 21241542 DOI: 10.3779/J.Issn.1009-3419.2004.04.03 |
0.396 |
|
| 2004 |
Sy SM, Wong N, Lee TW, Tse G, Mok TS, Fan B, Pang E, Johnson PJ, Yim A. Distinct patterns of genetic alterations in adenocarcinoma and squamous cell carcinoma of the lung. European Journal of Cancer (Oxford, England : 1990). 40: 1082-94. PMID 15093586 DOI: 10.1016/J.Ejca.2004.01.012 |
0.315 |
|
| 2004 |
Chan AT, Ngan R, Teo P, Leung SF, Yiu HY, Yeo W, Mok T, Cheung FY, Kwan W, Zee B. Final results of a phase III randomized study of concurrent weekly cisplatin-RT versus RT alone in locoregionally advanced nasopharyngeal carcinoma (NPC) Journal of Clinical Oncology. 22: 5523-5523. DOI: 10.1200/Jco.2004.22.90140.5523 |
0.41 |
|
| 2003 |
Hui EP, Poon TC, Teo PM, Mo F, Zee B, Leung SF, Ho S, Mok TS, Kwan WH, Johnson PJ, Chan AT. A prospective study of pre-treatment cell kinetics and clinical outcome in nasopharyngeal carcinoma. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 69: 53-62. PMID 14597357 DOI: 10.1016/S0167-8140(03)00248-2 |
0.346 |
|
| 2003 |
Sy SM, Wong N, Mok TS, Tsao MS, Lee TW, Tse G, Blackhall FH, Johnson PJ, Yim AP. Genetic alterations of lung adenocarcinoma in relation to smoking and ethnicity. Lung Cancer (Amsterdam, Netherlands). 41: 91-9. PMID 12826317 DOI: 10.1016/S0169-5002(03)00138-7 |
0.384 |
|
| 2003 |
Lee TW, Chen GG, Xu H, Yip JHY, Chak ECW, Mok TS, Yim APC. Differential expression of inducible nitric oxide synthase and peroxisome proliferator-activated receptor gamma in non-small cell lung carcinoma. European Journal of Cancer. 39: 1296-1301. PMID 12763220 DOI: 10.1016/S0959-8049(02)00733-5 |
0.414 |
|
| 2003 |
Mok TS, Chan AT. Nonplatinum-based chemotherapy for advanced non-small cell lung cancer Clinical Pulmonary Medicine. 10: 143-153. DOI: 10.1097/01.Cpm.0000059369.04504.D5 |
0.509 |
|
| 2002 |
Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW, Yim A, Chan AT, Yeo W, Chak K, Johnson P. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Cancer. 95: 1511-9. PMID 12237920 DOI: 10.1002/Cncr.10836 |
0.372 |
|
| 2002 |
Mok TS, Zee B. Adequate lymph node staging is fundamental to comparative study on resectable non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2604-5; author reply. PMID 12011141 DOI: 10.1200/Jco.2002.20.10.2604 |
0.401 |
|
| 2002 |
Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 10: 139-45. PMID 11862503 DOI: 10.1007/S00520-001-0321-4 |
0.347 |
|
| 2002 |
Ng CS, Zhang J, Wan S, Lee TW, Arifi AA, Mok T, Lo DY, Yim AP. Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer. Journal of Surgical Oncology. 79: 101-6. PMID 11815997 DOI: 10.1002/Jso.10046 |
0.485 |
|
| 2000 |
Mok T, Nguyen B, Chan A, Zee B, Yim A, Yang WY, Wong H, Yeo W, Leung TWT, Chak K, Johnson PJ. Gemcitabine-based combination chemotherapy for advanced non-small cell lung cancer: A new generation of therapy without cisplatin Lung Cancer. 29: 32-33. DOI: 10.1016/S0169-5002(00)80103-8 |
0.499 |
|
| 1999 |
Mok TS, Leung TW, Lee SD, Chao Y, Chan AT, Huang A, Lui MC, Yeo W, Chak K, Johnston A, Johnson P. A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology. 44: 307-11. PMID 10447578 DOI: 10.1007/S002800050982 |
0.336 |
|
| 1998 |
Yeo W, Leung TWT, Chan AT, Chiu SKW, Yu P, Mok TS, Johnson PJ. A Phase II Study of Combination Paclitaxel and Carboplatin in Advanced Nasopharyngeal Carcinoma European Journal of Cancer. 34: 2027-2031. PMID 10070305 DOI: 10.1016/S0959-8049(98)00280-9 |
0.389 |
|
| 1998 |
Mok TS, Steinberg J, Chan AT, Yeo WM, Hui P, Leung TW, Johnson P. Application of the International Prognostic Index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma Cancer. 82: 2439-2448. PMID 9635538 DOI: 10.1002/(Sici)1097-0142(19980615)82:12<2439::Aid-Cncr19>3.0.Co;2-Q |
0.373 |
|
| Show low-probability matches. |